Hemolytic C-Type Lectin CEL-III from Sea Cucumber Expressed in Transgenic Mosquitoes Impairs Malaria

合集下载

端粒酶抑制剂伊美司他治疗血小板增多IF56

端粒酶抑制剂伊美司他治疗血小板增多IF56

T h e ne w engl a nd jour na l o f medicineFrom the Department of Hematology, University Hospital of B ern and Univer-sity of B ern, B ern, Switzerland (G.M.B., E.O.L., M.D.); the Department of Hema-tology, School of Medicine, Cardiff Uni-versity, Cardiff, United Kingdom (O.G.O.); Upstate Oncology Associates, Greenville, SC (G.S.); the Section of Hematology and Oncology, University of Chicago, Chica-go (O.O.); the Divisions of Hematologic Malignancies and Hematology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Med-icine, B altimore (M.A.M.); the Depart-ment of Hematology, University Hospital Essen, Essen, Germany (A.R.); and Geron, Menlo Park (B.B., M.S.), and the Depart-ment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Gehr Family Center for Leukemia Research, Duarte (D.S.S.) — both in California. Ad-dress reprint requests to Dr. Baerlocher at the Department of Hematology, Stem Cell and Molecular Diagnostics Labora-tory, Freiburgstr. 4, Inselspital, University Hospital of Bern, CH-3010 Bern, Switzer-land,or at g abriela.b aerlocher@i nsel.c h. N Engl J Med 2015;373:920-8.DOI: 10.1056/NEJMoa1503479Copyright © 2015 Massachusetts Medical Society.BACKGROUNDImetelstat, a 13-mer oligonucleotide that is covalently modified with lipid exten-sions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this phase 2 study, we investigated whether ime-telstat could elicit hematologic and molecular responses in patients with essential thrombocythemia who had not had a response to or who had had unacceptable side effects from prior therapies.METHODSA total of 18 patients in two sequential cohorts received an initial dose of 7.5 or9.4 mg of imetelstat per kilogram of body weight intravenously once a week until attainment of a platelet count of approximately 250,000 to 300,000 per cubic milli-meter. The primary end point was the best hematologic response.RESULTSImetelstat induced hematologic responses in all 18 patients, and 16 patients (89%) had a complete hematologic response. At the time of the primary analysis, 10 pa-tients were still receiving treatment, with a median follow-up of 17 months (range, 7 to 32 [ongoing]). Molecular responses were seen in 7 of 8 patients who were positive for the JAK2 V617F mutation (88%; 95% confidence interval, 47 to 100). CALR and MPL mutant allele burdens were also reduced by 15 to 66%. The most common adverse events during treatment were mild to moderate in severity; neu-tropenia of grade 3 or higher occurred in 4 of the 18 patients (22%) and anemia, headache, and syncope of grade 3 or higher each occurred in 2 patients (11%). All the patients had at least one abnormal liver-function value; all persistent elevations were grade 1 or 2 in severity.CONCLUSIONSRapid and durable hematologic and molecular responses were observed in patients with essential thrombocythemia who received imetelstat. (Funded by Geron; number, NCT01243073.)ABSTR ACTTelomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaGabriela M. Baerlocher, M.D., Elisabeth Oppliger Leibundgut, Pharm.D.,Oliver G. Ottmann, M.D., Gary Spitzer, M.D., Olatoyosi Odenike, M.D., Michael A. McDevitt, M.D., Ph.D., Alexander Röth, M.D., Michael Daskalakis, M.D., Bart Burington, Ph.D., Monic Stuart, M.D.,and David S. Snyder, M.D.Imetelstat in Essential ThrombocythemiaE ssential thrombocythemia, a myelo-proliferative neoplasm, is a clonal disorderof a multipotent hematopoietic progenitor cell.1,2 The disease is associated with an in-creased risk of thrombotic complications, hemor-rhagic complications, or both, and can evolve into myelofibrosis or, in rare cases, can trans-form to acute leukemia.3 Common mutations associated with essential thrombocythemia are found in the Janus kinase 2 (JAK2) gene, the gene encoding the thrombopoietin receptor (MPL), and the calreticulin (CALR) gene.4-8 Cur-rent standard therapies for high-risk patients with essential thrombocythemia induce nonspe-cific reductions in platelet counts but do not typically eliminate or alter the biologic charac-teristics of the disease.9-12We have reported that telomerase activity in malignant cells obtained from patients with es-sential thrombocythemia and induced telomerase activity in cells isolated from healthy donors were inhibited by the telomerase inhibitor imetelstat.13 However, imetelstat inhibited spontaneous pro-liferation of megakaryocytic colonies obtained from patients with essential thrombocythemia but did not inhibit cytokine-induced megakaryo-cytic colonies from healthy donors. These find-ings suggest an intrinsic sensitivity of essential-thrombocythemia megakaryocytes to telomerase inhibition.13Imetelstat, a 13-mer thiophosphoramidate oli-gonucleotide that is covalently modified with lipid extensions, inhibits telomerase enzymatic activity14 (see the Supplementary Background sec-tion in the Supplementary Appendix, available with the full text of this article at ). In this phase 2 study, we investigated whether im-etelstat could elicit hematologic and molecular responses in patients with essential thrombocy-themia who had disease that was refractory to prior therapies or who had had unacceptable side-effects from previous therapies.MethodsEligibility CriteriaPatients who were 18 years of age or older and had received a diagnosis of essential thrombocy-themia defined according to World Health Orga-nization criteria15 (Table S1 in the Supplemen-tary Appendix) were eligible for enrollment if they required cytoreduction because of a platelet count higher than 600,000 per cubic millimeter and if they had not had a response to or had had unacceptable side effects from at least one prior therapy or if they declined to receive standard therapy. Additional inclusion and exclusion cri-teria are described in the Supplementary Ap-pendix.Study DesignThis was a phase 2, open-label study that was conducted at seven sites in the United States, Germany, and Switzerland; enrollment occurred during the period from January 2010 through January 2013. Patients were enrolled into se-quential cohorts that received weekly doses of 7.5 or 9.4 mg of imetelstat per kilogram of body weight, intravenously, until a platelet count of approximately 250,000 to 300,000 per cubic milli-meter was achieved or toxic effects occurred. Maintenance dosing at a reduced frequency be-gan after a patient had a complete or partial hematologic response (Table S2 in the Supple-mentary Appendix), with doses (7.5 to 11.7 mg per kilogram) adjusted according to the patient’s response and the side-effect profile of the drug. Additional details regarding the study design are provided in the Supplementary Appendix.The primary end point of the study was the best overall hematologic response, which was defined according to the platelet response com-ponent of the 2009 European LeukemiaNet (ELN) response criteria16 (Table S2 in the Supplemen-tary Appendix). Secondary end points included the frequency and severity of adverse events, the duration of hematologic response, the ELN “clin-icohematologic” response, and the molecular response in patients with JAK2 V617F mutations (Table S2 in the Supplementary Appendix), MPL W515L or MPL W515K mutations, or CALR mu-tations.All patients were assessed for JAK2 V617F, MPL W515L, MPL W515K, and CALR mutations at baseline and were reassessed every 12 weeks (±4 weeks) (see the Supplementary Methods sec-tion in the Supplementary Appendix). Patients who were enrolled in Europe underwent testing of spontaneous growth inhibition of mega-karyocyte colony-forming units (CFUs) (see the Supplementary Methods section in the Supple-mentary Appendix).T h e ne w engl a nd jour na l o f medicineSafety AssessmentData were collected on the extent of imetelstat exposure and on all adverse events. Adverse events were summarized according to terms used in the Medical Dictionary for Regulatory Activities, and severity was assessed with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE),17 version 4.03. For events with varying severity, the maxi-mum reported grade was used in summaries. Laboratory abnormalities were defined accord-ing to normal laboratory ranges from each insti-tution and converted to CTCAE grades.Study OversightThis phase 2 study was approved by the institu-tional review board at each participating site. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provid-ed written informed consent.The sponsor, Geron, provided the study drug and in collaboration with the authors designed the study and analyzed the data. The first author wrote the initial draft, and subsequent drafts were written by all authors with assistance from medical writers paid by Janssen Research and Development. All the authors made the decision to submit the manuscript for publication and vouch for the accuracy and completeness of the data and analyses and for adherence to the study protocol, which is available at . Clini-cal-trial agreements between the sponsor and the authors’ institutions included confidentiality provisions.Statistical AnalysisThe analysis of the primary end point of hema-tologic response included all patients who re-ceived at least one dose of imetelstat. The analy-sis of the duration of response included all patients who had a response. The analysis of molecular response included patients who re-ceived at least one dose of imetelstat and who had a JAK2 V617F, MPL W515L, MPL W515K, or CALR mutant allele burden at baseline. For re-sponse end points, exact 95% confidence inter-vals were calculated. The duration of hemato-logic response was estimated with the use of the Kaplan–Meier method. Patients who were lost to follow-up, discontinued the study, or began to receive other essential thrombocythemia–directed therapy before a hematologic response was documented and confirmed were counted as not having had a response. Safety analyses included all patients who received at least one dose of imetelstat.R esultsPatientsA total of 18 patients were enrolled in the study, and all had received one or more previous treat-ments; 17 had received hydroxyurea (94%), 13 had received anagrelide (72%), and 4 had received interferon (22%) (Table 1). Nine of the 18 pa-tients (50%) had disease that was resistant to at least one prior therapy, and 14 (78%) had had unacceptable side effects from prior therapy. The median time from the initial diagnosis ofe ssential thrombocythemia to enrollment was7.2 years (range, 0.3 to 24.9), and the median baseline platelet count was 788,000 per cubic millimeter (range, 521,000 to 1,359,000). Fifteen patients had baseline mutant allele burdens (8 with JAK2 V617F mutations, 2 with MPL W515L or MPL W515K mutations, and 5 with CALR mu-tations) (Table 1). Table S3 in the Supplementary Appendix describes additional baseline charac-teristics of the patients.Primary Efficacy End Point and Key Secondary Efficacy End PointOf the 18 patients who received imetelstat, 7 re-ceived an initial dose of 7.5 mg per kilogram and 11 received 9.4 mg per kilogram intravenously. The overall rate of hematologic response was 100% (95% confidence interval [CI], 83 to 100), and 16 of the 18 patients (89%) had a complete hematologic response (95% CI, 65 to 99) (Fig. 1A). In the 2 patients with a partial hematologic re-sponse, the lowest platelet counts were 261,000 per cubic millimeter at 23 weeks and 56,000 per cubic millimeter at 18 weeks, but neither response was sustained. Among the 16 patients who had a complete hematologic response, the median time to a complete response was 6.1 weeks (range, 5.1 to 12.1); the median time to a com-plete response was similar in JAK2 V617F–posi-tive and JAK2 V617F–negative patients. A trend was observed toward a more rapid response in patients in whom the initial dose was 9.4 mg per kilogram than in those in whom the initial dose was 7.5 mg per kilogram (median, 6.1 vs. 12.1Imetelstat in Essential Thrombocythemia weeks), although the difference was not signifi-cant (P = 0.71).During maintenance dosing, intermittent dos-ing was attempted in most patients and thefrequency of dosing generally decreased withtime; all the patients who had a complete hema-tologic response received a dose every 2 weeksor less frequently. At the time of the primaryanalysis, with a median follow-up of 17 months,10 of the 16 patients with a complete hemato-logic response (62%) were still receiving treat-ment, and the median duration of responsehad not been reached (follow-up range, 5 to 30months).While receiving the study treatment, one pa-tient had grade 2 bilateral retinal ischemia andwas recovering, and another had grade 2 lefthemiparesis and recovered; these thromboem-bolic events were assessed by the study investi-gators as being potentially related to underlyingessential thrombocythemia. The durations ofresponse ended at the reported onset of theseconditions, no further clinical follow-up infor-mation was obtained, and neither patient dis-continued imetelstat. Three patients had diseaseprogression from essential thrombocythemia tosecondary myelofibrosis, either during the studytreatment period or during the safety follow-upperiod.Other Secondary Efficacy End PointsMolecular ResponseA partial molecular response was detected inseven of eight patients with JAK2 V617F mutationsat baseline (88%; 95% CI, 47 to 100) (Fig. S1 inthe Supplementary Appendix). The median JAK2V617F mutant allele burden was reduced by 71%at month 3 after the initiation of treatment andremained reduced by 59% at month 12 despiteless frequent maintenance dosing (Fig. 1B).MPL W515L, MPL W515K, and CALR mutantallele burdens were also reduced, by 15 to 66%. Further information is provided in Table S4 in the Supplementary Appendix.Inhibition of ProliferationA megakaryocyte CFU assay was performed in five patients. It showed substantial inhibition of spontaneous proliferation at 1 month after ini-tiation of imetelstat treatment, with a median 92% reduction from baseline (Table S5 in the Supplementary Appendix).ELN “Clinicohematologic” ResponseResults with respect to the secondary end pointof a “clinicohematologic” response according toELN criteria16 (see Table S2 of the Supplementary Appendix) were similar to those of the primaryend point. A complete ELN clinicohematologic response was observed in 17 of the 18 patients (94%), and a partial response was observed in1 patient (6%). In 1 patient, splenomegaly thatwas palpable at 3 cm at baseline became nonpal-pable after the first cycle of treatment. None of* O ne patient did not meet the inclusion criteria for the minimum baseline platelet count, but the investigator thought that cytoreductive therapy was clinically indicated.† T hree patients had no mutation.T h e ne w engl a nd jour na l o f medicinethe 18 patients had constitutional symptoms at baseline.Telomerase Activity, Telomere Length, and Bone Marrow ResponseFigure S3 in the Supplementary Appendix shows telomerase activity. Assessments of telomere length and bone marrow response are described in the text of the Supplementary Appendix.S afetyThe most frequent adverse events that occurred during treatment (those that occurred in 50% or more of the patients and selected clinically sig-nificant adverse events) are listed in Table 2. All adverse events are listed in Table S6 in the Sup-plementary Appendix. Adverse events were re-ported in all patients, and 15 of the 18 patients (83%) reported at least one event of grade 3 or higher. Eighteen events of grade 3 or higher were attributed to imetelstat by the investigators, including neutropenia, headache, anemia, and a syncopal episode due to an infusion reaction (a second syncopal episode in the same patient was deemed to be unrelated to imetelstat). One grade 4 adverse event (a femoral-neck fracture) was reported by the treating clinician as being unrelated to imetelstat (Table S6 in the Supple-mentary Appendix). Eight of the 18 patients (44%) discontinued the study (Table S7 in the Supplementary Appendix).The most common nonlaboratory adverse events attributed to imetelstat were fatigue (in 15 of the 18 patients), nausea (in 12), diarrhea (in 11), and headache (in 8) (Table S8 in the Supplemen-tary Appendix). Infections occurred during treat-ment in 17 of the 18 patients (94%); 15 of these 17 patients (88%) had infections of grade 2 or lower. The most common infections were upper respiratory infections (in 39% of the patients), urinary tract infections (in 22%), and influenza (diagnosed on the basis of clinical and labora-tory findings), nasopharyngitis, and rash (each in 17%). The infections lasted less than 3 weeks in 81% of the patients and were not typically as-sociated with cumulative imetelstat exposure or with concurrent neutropenia or lymphopenia.At least one increase in grade, from baseline, in a liver-function value was observed in all 18 patients (Table 3). The majority of patients had grade 1 increases in alanine aminotransferase levels, with accompanying grade 1 increases in aspartate aminotransferase levels (the latter per-Figure 1. Hematologic and Molecular Responses in Patients Who Received Imetelstat.Panel A shows the hematologic response according to mutation status (cal-reticulin [CALR ], Janus kinase 2 [JAK2] V617F, MPL W515L or MPL W515K mutations, or no mutation). A complete hematologic response was observed in 16 of the 18 patients in the study (89%), and a partial hematologic response (“no complete response”) was observed in 2 patients (11%). The median time to a complete hematologic response was 1.4 months. Percentages shown are the best percent change in the mutant allele burden from base-line. Panel B shows the molecular response in JAK2 V617F–positive patients after treatment with imetelstat. The median JAK2 V617F mutant allele bur-den was reduced by 71% at month 3 and by 59% at month 12 despite less frequent maintenance dosing. I bars indicate 95% confidence intervals. The percent change shown is the median percent change in the JAK2 V617F mutant allele burden from baseline.CALR−31−36−48−55−15JAK2 V617FNo mutation04628121026181614282220243230MonthsB Molecular ResponseA Hematologic ResponseTime to first platelet count of 400×103/mm 3Time to complete responseNocomplete responseTreatment continuedM e d i a n J A K 2 V 617F (p e r c e n t c h a n g e f r o m b a s e l i n e )C h a n g e f r o m B a s e l i n e (%)−40−20−60−80−100Baseline 3691215MonthsP=0.001No. at Risk Percent Change88−718−688−727−595−52Discontinuation of treatment−96−82MPL−93−24−90−72−96−82−66−16−50−25Imetelstat in Essential Thrombocythemia sisted with ongoing imetelstat treatment). With-in 4 weeks after the initiation of imetelstat treat-aminotransferase level of 5 to 7 times the stan-dard upper limit of the normal range (grade 3)and concurrent increases in the aspartate ami-notransferase level of 2 to 6 times the standardupper limit of the normal range (grades 1 to 3)with dose reduction and did not recur with con-tinued treatment. With a longer duration oftreatment, persistent (≥6 weeks) grade 1 in-creases in alkaline phosphatase levels were ob-served in 14 of the 18 patients; these increaseswere associated with grade 1 or 2 unconjugated hyperbilirubinemia in 4 patients (Table 3).In post-study follow-up safety assessments,among the 14 patients who had persistent (≥6weeks) abnormalities in liver-function values, 11(79%) had values that reversed to normal orbaseline values. In 3 patients, the liver-functionvalues did not return to the upper limit of thenormal range; all hepatic biochemical abnor-malities in 2 of these patients improved, withcomplete resolution of the abnormal values, andthe 1 remaining patient whose condition wasnot improving at the end of follow-up had pro-patients who underwent extended follow-up forpersistent (≥6 weeks) abnormalities on liver-function tests, the median time to resolutionafter discontinuation of treatment was 12 weeks.The observed resolutions of these abnormalitiesfollowed permanent discontinuation of ime-telstat in all patients as the result of a full clini-cal hold issued by the Food and Drug Adminis-tration (FDA) (see the Discussion section).After the primary analysis was performed inOctober 2013, one patient who had received im-etelstat for approximately 3 years died frommonths after discontinuation of treatment. Cir-rhosis, secondary to hepatic steatosis, was thesuspected underlying disease. Although the pa-tient’s age (83 years), multiple coexisting condi-tions (including a history of exposure to hepati-tis B), and concomitant medications confoundedassessment, imetelstat could not be conclusivelyexcluded as a contributory agent.Hematologic toxic effects, defined according to changes in laboratory results from baseline values, are listed in Table 4. Thrombocytopenia of less than grade 3 was seen in 9 of the 18 pa-tients (50%). Neutropenia was observed in 15 pa-tients (83%), including 7 with grade 3 neutrope-nia (39%) and 3 with grade 4 neutropenia (17%).* I ncluded are the adverse events that occurred in 50% or more of the patients and selected clinically significant adverse events, regardless of whether they were deemed to be related to the study drug. The grade of adverse event was defined on the basis of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).* L aboratory abnormalities were defined on the basis of normal laboratory rang-es at each institution and were graded according to the CTCAE. The maximum grade was calculated for patients who had an increase in grade, as compared with the baseline grade. There were no grade 4 increases.na l o f medicineNo cases of febrile neutropenia were reported,and no patients with grade 4 neutropenia had a concurrent infection. Lymphopenia was reported in 6 patients (33%), with one grade 3 event. Fif-teen patients (83%) had anemia, and 3 (17%) had grade 3 anemia. Three patients required red-cell transfusions, including a patient who had a postsurgical hemorrhage. Three reported cases of cytopenia led to dose reductions: one for grade 1 thrombocytopenia, one for grade 3 ane-mia in a patient who required a red-cell transfu-sion, and one for grade 3 neutropenia; all three cases resolved.DiscussionIn this study, imetelstat rapidly induced hemato-logic responses in patients with essential throm-bocythemia who had disease that was refractory to conventional therapies or who had had unac-ceptable side effects from conventional therapies. All the patients had a hematologic response, and 89% had a complete hematologic response, a rate that exceeded rates observed with hydroxyurea, anagrelide, and interferon treatment.12,18-21 Else-where in this issue of the Journal , Tefferi et al. report the results of a pilot study of imetelstat therapy showing the induction of complete or partial remissions, as well as molecular remis-sions, in a subgroup of patients with myelofi-brosis.22JAK2 V617F may provide a useful marker of neoplastic proliferation, and current therapies elicit molecular responses in only a minority of patients with this mutation.12,20,23,24 In contrast,a rapid, substantial reduction in mutant allele burden was observed in all JAK2 V617F–positive patients in this study; 88% of patients had a partial molecular response. Attenuation and loss of a molecular response later during therapy may be due in part to reduced-frequency maintenance dosing; this suggests that the duration of ime-telstat treatment was insufficient to eliminate all mutated committed and clonal primitive hema-topoietic progenitors. The decrease in the CALR and MPL mutant allele burdens provides support for the hypothesis that imetelstat can reduce the various malignant clones observed in myelopro-liferative neoplasms. The decrease in the mutant allele burden appeared to be more pronounced for the JAK2 V617F mutations than for the CALR mutations, possibly because of activation of telomerase reverse transcriptase by the Janus kinase–signal transducer and activator of tran-scription (JAK-STAT) signaling pathway in pa-tients with essential thrombocythemia who had JAK2 V617F mutations.25,26Megakaryocyte CFU assays that were used to more directly measure inhibition of proliferation showed more than 90% inhibition of baseline proliferation activity within 1 month after the initiation of treatment in four of the five patients tested. These data suggest that imetelstat may have a selective inhibitory effect on the growth of the neoplastic clone or clones that drive es-sential thrombocythemia.Although all the patients had hematologic responses, there were subsequent fluctuations above normal platelet levels in all patients. Re-sponses were considered to be durable if inter-mittent dosing restored and maintained the platelet count (≤600,000 per cubic millimeter for a partial response or ≤400,000 per cubic milli-meter for a complete response). Once an initial response was achieved, patients with platelet counts that were not controlled by maintenance dosing (i.e., platelet counts that were >600,000 per cubic millimeter in patients with a partial response or >400,000 per cubic millimeter in patients with a complete response) for at least 8 weeks were considered to have a loss of re-sponse. The reported complete hematologic re-sponses were durable but required ongoing ime-telstat therapy; interpatient variability was noted in the frequency of dosing required to manage platelet levels (every 2 weeks to every 4 weeks or more) (Fig. S2 in the Supplementary Appendix).* L aboratory abnormalities were defined on the basis of normal laboratory rang-es at each institution and were graded according to the CTCAE. The maxi-mum grade was calculated for patients who had an increase in grade, as com-pared with the baseline grade.Imetelstat in Essential ThrombocythemiaAfter discontinuation of treatment, increases in platelet counts were consistent with the main-tenance interval during treatment. Patients with longer treatment intervals had more gradual increases after discontinuation of treatment, whereas patients who required more frequent dosing had more rapid increases.At the time of the primary analysis, 10 pa-tients were still receiving treatment, with a median follow-up of 17 months (range, 7 to 32 [ongoing]). Of the adverse events attributed to imetelstat, most were mild to moderate; 18 events were of grade 3 or higher (Table S8 in the Sup-plementary Appendix). Upper respiratory infec-tions, which were reported in 6 of 18 patients (33%), were mostly mild to moderate and were not associated with myelosuppression or disease progression. Three patients had disease progres-sion from essential thrombocythemia to second-ary myelofibrosis, either during the study treat-ment period or during the safety follow-up period, and JAK inhibitor therapies were initiat-ed. Among these 3 patients, one had an unrelated grade 2 upper respiratory tract infection and grade 3 osteomyelitis and another had grade 2 influenza.In a study involving 1104 patients, the rates of progression from essential thrombocythemia and from early or prefibrotic primary myelofi-brosis to overt myelofibrosis were 0.8% and 12.3%, respectively, at 10 years and 9.3% and 16.9%, respectively, at 15 years.26 The prognostic variables associated with death or progression to leukemia or myelofibrosis were bone marrow histologic features (early or prefibrotic primary myelofibrosis vs. essential thrombocythemia), age (>60 years), history of thrombosis, leukocy-tosis, and anemia.27 The 3 patients in our study who had disease that progressed to myelofibro-sis had essential thrombocythemia for 12, 13, and 21 years and were 67, 61, and 56 years old, respectively, when myelofibrosis was diagnosed. Two of the 3 patients received the diagnosis near the date of their last dose of imetelstat, and 1 received the diagnosis 6 months after the last dose, during extended follow-up of liver func-tion. At baseline, 2 of the 3 patients had 1+ and 2+ reticulin fibrosis in the bone marrow, and the hemoglobin level in all 3 patients was lower than 12 g per deciliter. The rate of progression to myelofibrosis in the current study (17%; 3 of 18 patients) is higher than historical estimates; however, the small number of patients in this study and the presence of prognostic factors make cross comparisons difficult.Abnormal results of liver-function tests were observed frequently but were mostly mild in grade; one fatal event of bleeding esophageal varices occurred after the primary-analysis time point. On March 11, 2014, the FDA issued a full clinical hold on imetelstat, citing a lack of evi-dence of reversibility of hepatotoxicity, concern regarding a risk of chronic liver injury, and a lack of adequate follow-up in patients who had hepatotoxic effects. All the patients who were still receiving the study medication permanently discontinued active treatment and were observed for safety. Follow-up safety data showed that treatment-related abnormalities on liver-function tests resolved in most patients (Table S9 in the Supplementary Appendix), and the FDA lifted the clinical hold on October 31, 2014.In conclusion, imetelstat, a telomerase inhibi-tor, had a clinically significant effect on disease burden in patients with essential thrombocythe-mia who had not had a response to previous treatment or who had had unacceptable side ef-fects from conventional therapies. Neutropenia and abnormal liver-function tests were the main adverse events. Furthermore, molecular respons-es were observed in patients with mutated JAK2 and CALR molecular signatures; this finding suggests therapeutic activity in the malignant clones that are the underlying source of essential thrombocythemia.Supported by Geron.Disclosure forms provided by the authors are available with the full text of this article at .We thank the patients who volunteered to participate in this study and the study site staff who cared for them: Renata Bünter, Ursina Sager, Regula Jäggi, and Dr. Stephan Reichenbach at the Clinical Trials Unit of the University of Bern, Switzerland; Drs. Alexandre Theocharides, Gabi Vetsch, Giuseppe Colucci, and other members of the Clinical Hematology Team of the Univer-sity Hospital of Bern; Dr. Monika Haubitz, Dr. Meike Dahlhaus, Ingrid Helsen, Barbara Hügli, Elisabeth Ischi, and other mem-bers of the Experimental Hematology, Molecular Diagnostics, and Stem Cell Laboratory of Hematology teams of the University of Bern and University Hospital of Bern; the staff of Geron who were involved in data collection and analyses, including Dr. Joi Ninomoto for contributions to study design, and Ted Shih, Neeru Batra, Dianne Morfeld, and Raheela Kauser Steiner of Geron for their contributions to data acquisition, review, and interpreta-tion in previous studies and throughout the span of the trial; and Dr. Tracy T. Cao of Source One Technical Solutions and Dr. Namit Ghildyal of Janssen Research and Development, for edi-torial assistance with an earlier version of the manuscript.。

功能化氧化石墨烯携带PD-L1_siRNA抑制肝癌细胞的恶性生物学行为

功能化氧化石墨烯携带PD-L1_siRNA抑制肝癌细胞的恶性生物学行为

激光生物学报ACTA LASER BIOLOGY SINICAVol. 32 No. 4Aug . 2023第32卷第4期2023年8月收稿日期:2023-05-05;修回日期:2023-05-29。

基金项目:湖南省研究生科研创新项目(QL 20210136);2021年湖南省企业科技特派员项目(2021GK 5015);湖南省自然科学基金面上项目(2021JJ 30453);国家自然科学基金面上项目(81872256)。

作者简介:李志伟,博士研究生。

∗ 通信作者:李立民,讲师,主要从事生物材料与医用电子学方面的研究。

E-mail: fblwlee@ 。

功能化氧化石墨烯携带PD -L1 siRNA 抑制肝癌细胞的恶性生物学行为李志伟a ,单丽红a ,刘曦冉a ,闵 洋a ,丁小凤a ,李立民b*(湖南师范大学 a. 生命科学学院基因功能与调控研究室;b. 工程与设计学院,长沙 410081)摘 要:程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L 1)信号通路主要参与免疫负调控作用,且在许多类型的肿瘤的恶性发展中具有关键作用。

PD-L 1的高表达可促进肝细胞癌(HCC )的侵袭,提高肿瘤复发的风险。

另外,PD-L 1常作为免疫检查点的阻断靶点,主要通过单抗将其中和,引发抗肿瘤免疫反应。

因此,PD-L 1是HCC 免疫治疗中极具潜力的靶点之一。

本文主要探究纳米级功能化氧化石墨烯(GO-PEI-PEG )携带PD-L1 siRNA 对肝癌细胞的恶性生物学行为的影响。

研究结果显示,将GO-PEI-PEG/PD-L1 siRNA 转染至MHCC 97H 细胞后,细胞的增殖和迁移均被抑制,细胞周期阻滞在G 1期,且细胞凋亡的数目增多。

进一步研究发现,GO-PEI-PEG/PD-L1 siRNA 对MHCC 97H 细胞的抑制作用是通过阻碍AKT 信号通路激活实现的。

这些试验结果表明,GO-PEI-PEG 具备优秀的递送性能,携带PD-L1 siRNA 可有效干扰PD-L 1表达,进而抑制肝癌细胞的恶性生物学行为,这为治疗HCC 提供了更安全、有效的递送新策略。

常春藤皂苷元通过调控巨噬细胞Mincle介导的炎症减轻银屑病小鼠皮肤损伤的作用机制

常春藤皂苷元通过调控巨噬细胞Mincle介导的炎症减轻银屑病小鼠皮肤损伤的作用机制

◇基础研究◇摘要目的:观察常春藤皂苷元(hederagenin ,HDG )改善银屑病小鼠皮肤损伤和炎症的作用与机制。

方法:通过在C57小鼠背部祛毛并连续涂抹咪喹莫特7d 建立小鼠银屑病动物模型,造模后1h 给予HDG 灌胃治疗。

总计设置正常组、模型组、模型+HDG 低剂量(25mg ·kg -1·d -1)、模型+HDG 高剂量(50mg ·kg -1·d -1)和模型+卤米松阳性对照组(每组8只小鼠)。

给药7d 后,对患处皮肤进行病理检测,以及炎症指标进行ELISA 、实时定量PCR 检测,Mincle 及其下游信号进行免疫组织化学、免疫荧光和Western blot 检测。

结果:与模型组比较,HDG 干预组皮肤病理损伤以及炎性细胞浸润均得到不同程度改善;实时定量PCR 和皮肤组织悬液ELISA 结果证实HDG 干预后小鼠皮肤中炎症因子IL-1β、IL-6和TNF-α的mRNA 及蛋白水平均比模型组降低(P <0.01),说明HDG 具有显著抗炎症作用;免疫组织化学和Western blot 结果表明,与正常组相比,模型组小鼠皮肤中Min-cle 的蛋白表达量显著增加(P <0.01),给予HDG 干预后明显下调(P <0.01);免疫荧光证实模型组皮肤中Mincle 表达与巨噬细胞标志物F4/80共定位;Western blot 实验发现,HDG 在治疗组中不仅下调了Mincle 的蛋白表达,同时也下调了Mincle 下游信号Syk 和NF-κB 的蛋白磷酸化水平。

结论:HDG 可显著改善银屑病小鼠皮肤损伤和巨噬细胞相关炎症,其潜在分子机制可能与下调Min-cle/Syk/NF-κB 信号途径相关。

关键词常春藤皂苷元;Mincle ;皮肤损伤;炎症;银屑病中图分类号:R965.2文献标志码:A文章编号:1009-2501(2023)12-1339-08doi :10.12092/j.issn.1009-2501.2023.12.003银屑病是一种慢性丘疹鳞状皮肤病,其主要特点是遗传性和复发性,还可能并发其他疾病,如心血管疾病、糖尿病和关节炎等[1-4]。

血液系统疾病英文缩写

血液系统疾病英文缩写

AA:再生障碍性贫血(aplastic anemia)ACD:慢性病贫血(anemia of chronic disorders) aCML:不典范慢性粒细胞白血病(atypical chronic myeloid leukemia)AHA:自身免疫性溶血性贫血(autoimmune hemolytic anemia)AIHA:自身免疫性溶血性贫血(autoimmune hemolytic anemia)AL:急性白血病(acute leukemia)ALL:急性淋巴细胞性白血病(Acute lymphocytic leukemia)AML:急性粒细胞性白血病(Acute myelocytic leukemia)AMKL:急性巨核细胞白血病(acute megakaryocytic leukemia )ANLL:急性非淋巴细胞性白血病(acute nonlymphocytic leukemia )APA:急性失血性贫血(acute posthemorrhagic anemia)ATL:成人T细胞白血病/淋巴瘤(adult t-cell leukemia/lymphoma)ATP:自身免疫性血小板减少性紫癜(autoimmune thrombocytopenic purpura)BL:嗜碱性粒细胞白血病(basophilic leukemia) CDA:纯红细胞再生障碍性贫血(congenital dyserythropoietic anemia)CEL:慢性嗜酸性粒细胞白血病(chroniceosinophilic leukemia)CIMF:慢性特发性骨髓纤维化(chronic idiopathic myelofibrosis)CL:慢性白血病(chronic leukemia)CLL:慢性淋巴系白血病(chronic lymphoid leukemia) CLL:慢性淋巴细胞白血病(chronic lymphocyticleukemia)CLPD:慢性淋巴细胞增殖性疾病(chronic lymphoproliferative disorders)CML:慢性髓系白血病(chronic myeloid leukemia) CML:慢性髓细胞白血病(chronic myelocytic leukemia)CML:慢性粒细胞白血病(chronic myelocytic leukemia)CMML:慢性粒-单核细胞白血病(chronic myelomonocytic leukemia)CMPDs:慢性骨髓增殖性疾病(chronic myeloproliferative disorders)CNL:慢性中性粒细胞白血病(chronic neutrophilic leukemia)DIHA:药物性溶血性贫血(drug-induced hemolytic anemia)EL:嗜酸性粒细胞白血病(eosinophilic leukemia) HA:溶血性贫血(hemolytic anemia)HAL:低增生性急性白血病(hypoplastic acute leukemia)HCL:毛细胞白血病(hairy cell leukemia) HSP:过敏性紫癜又称亨-舒综合症(Henoch-Schonlein purpura)IDA:缺铁性贫血(iron deficiency anemia)IM:沾染性单核细胞增多症(Infectious Mononucleosis)IMF:原发性骨髓纤维化症(Idiopathic myelofibrosis)ITP:特发性血小板减少性紫癜(idiopathic thrombocytopenic purpura)JMML:幼年型粒-单核细胞白血病(juvenile myelomonocytic leukemia)LGLL:年夜颗粒淋巴细胞白血病(large granular lymphocytic leukemia)MA:地中海贫血(Mediterranean anemia)MA:巨幼细胞性贫血(megaloblastic anemia)MAL:急性混合细胞白血病(mixed acute leukemia) MCL:组织嗜碱细胞(肥年夜细胞)性白血病(mast call leukemia)MDS:骨髓增生异常综合征(myelodysplastic syndrome)MH:恶性组织细胞病(malignant histiocytosis) MH:恶性组织细胞增多症(malignant histiocytosis) ML:巨核细胞白血病(megakaryoblastic leukemia) MM:多发性骨髓瘤(multiple myeloma)PHT:原发性出血性血小板增多症(primary hemorrhagic thrombocythemia)PLL:幼淋巴细胞白血病(prolymphocytic leukemia) PNH:阵发性睡眠性血红卵白尿(paroxysmal nocturnal hemoglobinuria)PRCA:纯红细胞再生障碍性贫血(pure red cell aplasia)PS:纯真性紫癜(purpura simplex)PT:原发性或特发性血小板增多症(primary oridiopathic thrombocythemia)PV:真性红细胞增多症(polycythemia vera)RA:难治性贫血(refractory anemia)RARS:难治性贫血伴环状铁粒幼细胞RAWS:难治性贫血伴铁粒幼红细胞增多(refractory anemia with sideroblastosis)RCMD:难治性血细胞减少陪伴多系发育异常RCMD-RS:难治性血细胞减少陪伴多系发育异常和环状铁粒幼细胞SA:铁粒幼细胞改贫血(sideroblastic anemia) SCVL:绒毛淋巴细胞脾淋巴瘤(splenic lymphoma with circulating villous lymphocytes)ST:继发性或反应性血小板增多症(secondary thrombocythemia)TEG:嗜酸性粒细胞增多症(cal eosinophilic granulocytosis)TTP:血栓性血小板减少性紫癜(thrombotic。

恩曲替尼化学式-概述说明以及解释

恩曲替尼化学式-概述说明以及解释

恩曲替尼化学式-概述说明以及解释1.引言1.1 概述概述恩曲替尼(英文名称:Entrectinib)是一种靶向抗癌药物,属于酪氨酸激酶抑制剂。

它通过抑制肿瘤细胞中的激酶信号通路,发挥抗肿瘤的作用。

恩曲替尼被广泛应用于非小细胞肺癌、神经母细胞瘤和其他肿瘤的治疗。

该药物的化学性质使其具备出色的抗肿瘤效果。

恩曲替尼的分子式为C31H34Cl2N5O3,分子量为602.54克/摩尔。

其分子结构复杂,由多个不同原子组成的编织网状结构构成。

这种特殊的结构赋予了恩曲替尼优异的特性,包括其强大的抑制肿瘤生长能力和独特的靶向治疗机制。

除了化学性质外,恩曲替尼还具有一系列独特的物理性质。

该药物为白色或类白色结晶粉末,具有极高的纯度要求。

其熔点为210-215,在这个温度范围内可以保持稳定。

此外,恩曲替尼在常温下可溶于一些有机溶剂,如二氯甲烷和二甲基亚砜,但不溶于水。

在药理作用方面,恩曲替尼主要表现出针对肿瘤细胞的抗增殖和抗转移能力。

它通过干扰肿瘤细胞的激酶信号通路,阻止肿瘤细胞的分裂和生长。

此外,恩曲替尼还具有特异性靶向治疗作用,能够选择性地抑制特定的激酶,从而实现精确的治疗效果。

然而,恩曲替尼也存在一些副作用,如恶心、呕吐、疲劳和食欲不振等,这些副作用需在使用时留意并及时处理。

综上所述,恩曲替尼作为一种靶向抗肿瘤药物,具有复杂的化学性质、独特的物理性质以及较广泛的药理作用。

进一步的研究和应用将有助于更好地发掘恩曲替尼的潜力,为肿瘤治疗提供新的突破和可能性。

1.2 文章结构文章结构部分的内容如下:文章结构部分主要介绍了整篇文章的组织结构和内容安排。

本文的目录分为引言、正文和结论三个部分。

引言部分主要是对整篇文章的背景和目的进行概述,并对恩曲替尼的化学式进行引入。

接着,文章结构部分将详细介绍恩曲替尼的化学性质、物理性质和药理作用。

最后,结论部分将对恩曲替尼的化学性质、物理性质和药理作用进行总结。

在正文部分,恩曲替尼的化学性质将包括分子式、分子量和结构式的介绍。

《临床肝胆病杂志》推荐使用的规范医学名词术语

《临床肝胆病杂志》推荐使用的规范医学名词术语

临床肝胆病杂志第40卷第3期2024年3月J Clin Hepatol, Vol.40 No.3, Mar.2024[3]XIA SL, LIU ZM, CAI JR, et al. Liver fibrosis therapy based on biomi⁃metic nanoparticles which deplete activated hepatic stellate cells[J]. J Control Release, 2023, 355: 54-67. DOI: 10.1016/j.jconrel.2023.01.052.[4]LIU YW, DONG YT, WU XJ, et al. The assessment of mesenchymalstem cells therapy in acute on chronic liver failure and chronic liver disease: A systematic review and meta-analysis of randomized con⁃trolled clinical trials[J]. Stem Cell Res Ther, 2022, 13(1): 204. DOI:10.1186/s13287-022-02882-4.[5]ZHANG ZL, SHANG J, YANG QY, et al. Exosomes derived from hu⁃man adipose mesenchymal stem cells ameliorate hepatic fibrosis by inhibiting PI3K/Akt/mTOR pathway and remodeling choline me⁃tabolism[J]. J Nanobiotechnology, 2023, 21(1): 29. DOI: 10.1186/ s12951-023-01788-4.[6]ZHAO T, SU ZP, LI YC, et al. Chitinase-3 like-protein-1 function andits role in diseases[J]. Signal Transduct Target Ther, 2020, 5(1): 201. DOI: 10.1038/s41392-020-00303-7.[7]YANG H, ZHAO LL, HAN P, et al. Value of serum chitinase-3-likeprotein 1 in predicting the risk of decompensation events in patients with liver cirrhosis[J]. J Clin Hepatol, 2023, 39(7): 1578-1585. DOI:10.3969/j.issn.1001-5256.2023.07.011.杨航, 赵黎莉, 韩萍, 等. 血清壳多糖酶3样蛋白1(CHI3L1)对肝硬化患者发生失代偿事件风险的预测价值[J]. 临床肝胆病杂志, 2023, 39(7): 1578-1585. DOI: 10.3969/j.issn.1001-5256.2023.07.011.[8]MA L, WEI J, ZENG Y, et al. Mesenchymal stem cell-originated exo⁃somal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis[J]. Drug Deliv, 2022, 29(1): 440-453. DOI: 10.1080/10717544.2022.2030428. [9]NISHIMURA N, DE BATTISTA D, MCGIVERN DR, et al. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis[J]. Proc Natl Acad Sci U S A, 2021, 118(17): e2019633118. DOI: 10.1073/pnas.2019633118.[10]WANG CG, LI SZ, SHI JM, et al. Research progress in differentia⁃tion, identification, and purification methods of human pluripotent stem cells to mesenchymal-like cells in vitro[J]. J Jilin Univ Med Ed, 2023, 49(6): 1655-1661. DOI: 10.13481/j.1671-587X.20230634.王成刚, 李生振, 史嘉敏, 等. 体外人多能干细胞向间充质样细胞分化、鉴定和纯化方法的研究进展[J]. 吉林大学学报(医学版), 2023, 49(6): 1655-1661. DOI: 10.13481/j.1671-587X.20230634.[11]LI TT, WANG ZR, YAO WQ, et al. Stem cell therapies for chronicliver diseases: Progress and challenges[J]. Stem Cells Transl Med, 2022, 11(9): 900-911. DOI: 10.1093/stcltm/szac053.[12]YANG X, LI Q, LIU WT, et al. Mesenchymal stromal cells in hepaticfibrosis/cirrhosis: From pathogenesis to treatment[J]. Cell Mol Im⁃munol, 2023, 20(6): 583-599. DOI: 10.1038/s41423-023-00983-5. [13]ZHAO SX, LIU Y, PU ZH. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apop⁃tosis by activating autophagy in vitro[J]. Drug Des Devel Ther, 2019, 13: 2887-2897. DOI: 10.2147/DDDT.S220190.[14]LEE CG, HARTL D, LEE GR, et al. Role of breast regression protein39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue re⁃sponses and apoptosis[J]. J Exp Med, 2009, 206(5): 1149-1166.DOI: 10.1084/jem.20081271.[15]HIGASHIYAMA M, TOMITA K, SUGIHARA N, et al. Chitinase 3-like 1deficiency ameliorates liver fibrosis by promoting hepatic macro⁃phage apoptosis[J]. Hepatol Res, 2019, 49(11): 1316-1328. DOI:10.1111/hepr.13396.收稿日期:2023-06-09;录用日期:2023-08-17本文编辑:邢翔宇引证本文:LIU PJ, YAO LC, HU X, et al. Effect of human umbilical cord mesenchymal stem cells in treatment of mice with liver fibrosis and its mechanism[J]. J Clin Hepatol, 2024, 40(3): 527-532.刘平箕, 姚黎超, 胡雪, 等. 人脐带间充质干细胞(hUC-MSC)对肝纤维化小鼠模型的治疗作用及其机制分析[J]. 临床肝胆病杂志, 2024, 40(3): 527-532.读者·作者·编者《临床肝胆病杂志》推荐使用的规范医学名词术语有关名词术语应规范统一,以全国自然科学名词审定委员会公布的各学科名词为准。

不仅仅是保健品,特殊结构的胶原蛋白或可成为抗癌靶点

不仅仅是保健品,特殊结构的胶原蛋白或可成为抗癌靶点

不仅仅是保健品,特殊结构的胶原蛋白或可成为抗癌靶点原创药明康德药明康德2022-08-01 07:30发表于美国说起胶原蛋白,或许人们最先想到的是超市货架上琳琅满目的胶原蛋白保健品,事实上I型胶原蛋白是人体内含量最为丰富的蛋白质之一,广泛存在于骨骼、肌腱和皮肤组织中。

关于胶原蛋白补充剂在改善皮肤和关节健康中的作用仍旧充满争议,现在,科学家发现比起作为功效不明的保健品,胶原蛋白可能有一个更大的用处:抗击癌症。

最近发表在Cancer Cell的一篇研究发现癌细胞通过产生特异性结构的胶原蛋白,保护其免于机体免疫反应的伤害,而靶向破坏这种特定结构的胶原蛋白可以减少癌细胞增殖、提高免疫治疗的效力。

胶原蛋白作为细胞外基质的一部分,一般情况下它由两条α1链和一条α2链组装形成三螺旋蛋白结构。

然而,在研究人类胰腺癌细胞系时,研究人员发现这些癌细胞仅表达了编码α1链的基因(COL1a1),而相比之下胶原蛋白的“生产大户”成纤维细胞则可以同时表达这两种基因。

进一步的分析发现,癌细胞通过表观遗传调控手段,使编码α2链的基因(COL1a2)发生超甲基化来实现基因沉默,以此产生由三个α1链组成的癌症特异性胶原蛋白“同源三聚体”结构。

为探明这一特殊的蛋白结构对于癌细胞生存和增殖的意义,研究人员构建了COL1a1特异性敲除的胰腺癌小鼠模型,这种小鼠体内癌细胞的COL1a1基因处于沉默状态,故而癌细胞无法产生具有α1同源三聚体结构的胶原蛋白。

这种癌症特异性α1同源三聚体结构的缺失显著减少了癌细胞增殖并引发了癌症微生物组的重编程。

这些变化削弱了肿瘤免疫抑制作用,并伴随着T细胞浸润增加以及癌细胞数量的减少。

不仅如此,COL1a1敲除小鼠对于抗PD-1疗法的应答明显增强,这些发现提示,由三个α1链组成的胶原蛋白同源三聚体结构对于维持癌细胞增殖和免疫抑制作用至关重要,靶向破坏这种“同源三聚体”结构胶原蛋白可以显著提升免疫疗法的抗癌效力。

检验专业英语试题及答案

检验专业英语试题及答案

检验专业英语试题及答案一、选择题(每题2分,共20分)1. Which of the following is not a routine test in clinical laboratory?A. Blood countB. Urine analysisC. Liver function testD. DNA sequencing2. The term "hemoglobin" refers to:A. A type of proteinB. A type of enzymeC. A type of hormoneD. A type of lipid3. What is the primary function of the enzyme amylase?A. To break down proteinsB. To break down carbohydratesC. To break down fatsD. To break down nucleic acids4. The process of identifying the presence of a specific microorganism in a sample is known as:A. CulturingB. IsolationC. IdentificationD. Quantification5. Which of the following is a common method for measuring the concentration of glucose in blood?A. SpectrophotometryB. ChromatographyC. ElectrophoresisD. Enzymatic assay6. The term "ELISA" stands for:A. Enzyme-Linked Immunosorbent AssayB. Electrophoresis-Linked Immunosorbent AssayC. Enzyme-Linked Immunofluorescence AssayD. Electrophoresis-Linked Immunofluorescence Assay7. In medical diagnostics, what does "PCR" refer to?A. Polymerase Chain ReactionB. Protein Chain ReactionC. Particle Count ReactionD. Pathogen Characterization Reaction8. The process of measuring the amount of a specific substance in a sample is known as:A. TitrationB. CalibrationC. QuantificationD. Qualification9. Which of the following is a common type of clinical specimen?A. BloodB. SoilC. HairD. Water10. The term "antibodies" refers to:A. Proteins that recognize and bind to specific antigensB. Substances that neutralize toxinsC. Hormones that regulate immune responseD. Cells that produce immune responses二、填空题(每空1分,共10分)1. The process of separating molecules based on their size is known as __________.2. In clinical chemistry, the term "assay" refers to a__________ method.3. The unit of measurement for pH is __________.4. A common method for detecting the presence of antibodies in a sample is the __________ test.5. The process of identifying the type of bacteria in a sample is known as __________.6. The process of separating DNA fragments based on their size is known as __________.7. The term "ELISA" is used in __________ to detect the presence of specific antibodies or antigens.8. The process of identifying the genetic makeup of an organism is known as __________.9. The process of measuring the amount of a substance in a sample using a specific wavelength of light is called__________.10. The process of identifying the presence of specific microorganisms in a sample is known as __________.三、简答题(每题5分,共20分)1. Describe the principle of the Enzyme-Linked Immunosorbent Assay (ELISA).2. Explain the importance of maintaining aseptic technique ina clinical laboratory.3. What are the steps involved in performing a blood count?4. Discuss the role of antibodies in the immune response.四、论述题(每题15分,共30分)1. Compare and contrast the methods of Chromatography and Electrophoresis in terms of their applications in clinical diagnostics.2. Discuss the ethical considerations in the use of genetic testing for medical purposes.五、翻译题(每题5分,共10分)1. 将以下句子从中文翻译成英文:在临床实验室中,酶联免疫吸附测定法是一种常用的检测特定抗体或抗原的方法。

肝病专业英语词汇

肝病专业英语词汇

3α-羟类固醇脱氢酶(Y' 蛋白) γ -谷氨酰转移酶 γ-氨基丁酸 甲胎蛋白 人兽共患病 异种肝移植 脂肪性纤维瘤,黄色瘤 黄嘌呤氧化酶 黄斑瘤 全球移植中心名录 窗口期 肝豆状核变性 肥达反应 外斐反应 韦克斯勒成人智力测验 呕吐 视觉诱发电位 病毒学应答 病毒复制 病毒性肝炎 静脉-静脉转流 VOD 肝小静脉闭塞病 静脉-动脉转流 血管活性肽 静脉曲张 胆管消失综合征 疫苗 熊去氧胆酸 尿胆素原 尿胆素 二磷酸尿苷异构酶 尿素生成 鸟氨酸循环,尿素循环 上消化道出血 粗纤维调节素 肝未分化肉瘤 充盈不足学说 非结合高胆红素血症 游离胆红素,非结合胆红素 超声(波)检查法
短潜伏期肝炎 移动性浊音 腹水白蛋白浓度梯度 血清肝炎 血清诊断 血清胆红素 血清白蛋白 血清学应答 乙肝血清学检查 血清转换 败血症相关胆汁淤积 正链,有义链 镇静剂 次级胆酸 海蓝组织细胞增多症 硬化疗法 硬化性胆管炎 日本血吸虫病 湄公血吸虫 曼氏血吸虫 日本血吸虫 间插血吸虫 埃及血吸虫 血吸虫 瘢痕形成期 粗面内质网 滚环机制(环状DNA复制的机理) RNA干扰 核酶 核糖体 胆固醇逆向转运
伤寒 Ⅳ型胶原 Ⅲ型前胶原 甲肝和乙肝疫苗 抑癌基因 肿瘤坏死因子 肝结核 滋养体 甘油三酯 颠换效应 经颈静脉肝内门腔分流 转换 输血传染的病毒 输血性肝炎 转化生长因子
transcatheter arterial chemoembolization 肝动脉化疗栓塞 trans-activation toxic hepatitis total cholesterin total bilirubin tomor necrosis factor tocopherol TNF-related apoptosis inducing ligand tissue inhibitor of metalloproteinase thymosin Thymopolypeptides for Injection thromboxane the core promoter element tentative diagnosis tension of muscle tenderness Telbivudine taurocholic acid taurochenodeoxycholate acid systemic inflammatory response syndrome syncytial giant-cell hepatitis sustained virus response sustained response 反式激活 中毒性肝炎 总胆固醇 总胆红素 肿瘤坏死因子 生育酚,维生素E 肿瘤坏死因子相关凋亡诱导配体 基质金属蛋白酶组织抑制物 胸腺肽 胸腺肽 血栓素 核心启动子元件,启动子核心元件 暂时的(假定的)诊断,试验性诊断 肌张力 压痛 LdT 牛(磺)胆酸 牛磺鹅(去氧)胆酸盐,牛磺鹅(脱氧)胆酸盐 全身炎症反应综合症 融合巨细胞性肝炎 持续病毒应答 持久应答

不同酶消化法提取猪原代肝细胞的效果比较

不同酶消化法提取猪原代肝细胞的效果比较

532024.4·试验研究0 引言猪圆环病毒(PCV )是Circoviridae 科Circovirus 属的一种无囊膜的单链环状DNA 病毒。

在已知的4个血清型中,PCV2为猪易感的致病性病毒[1]。

PCV2感染会诱导宿主免疫抑制引起猪圆环病毒病(PCVD ),包括断奶仔猪多系统衰竭综合征、新生仔猪先天性脑震颤、皮炎与肾病综合征、猪呼吸道病综合征、母猪繁殖障碍等,给全世界养猪业带来较大的经济损失,是世界各国的兽医与养猪业者公认的造成重大影响的猪传染病[2]。

PCV2的感染在猪生长发育的不同阶段有不同的组织嗜性。

但无论是胎儿阶段还是出生后,肝细胞都是PCV2感染和复制的靶细胞。

因此,PCV2也被视为一种能够诱导猪肝炎的病毒[3]。

且PCV2诱导的肝细胞凋亡在PCV2引发的相关病变和疾病的发病机制中具有关键性作用[4]。

因此,方便、快捷地获取大量有活性的猪肝细胞对于研究PCVD 的致病机制具有重大意义。

目前获取肝细胞常用的方法主要包括机械分离细胞法、非酶分离细胞法、离体酶消化法和酶灌流法等[5]。

因此,本试验采用简便、经济、无需特殊设备、仅需部分肝组织的离体酶消化法,比较不同酶消化分离猪原代肝细胞的效果,为一般实验室提取分离大量有活性的猪肝细胞提供参考。

1 材料与方法1.1 材料1.1.1 主要试剂新鲜猪肝组织,Hank's 平衡盐溶液(HBSS ),磷酸盐缓冲液(无菌PBS ),4%多聚甲醛(PFA ),收稿日期:2024-01-27基金项目:国家自然科学基金项目:复杂器官与组织在脾脏内的功能性再生(32230056)作者简介:周徐倩(1999-),女,汉族,浙江温州人,硕士在读,研究方向:组织工程与再生医学。

*通信作者简介:董磊(1978-),男,汉族,安徽阜阳人,博士,教授,研究方向:组织工程与再生医学、生物材料。

周徐倩,董磊.不同酶消化法提取猪原代肝细胞的效果比较[J].现代畜牧科技,2024,107(4):53-55. doi :10.19369/ki.2095-9737.2024.04.014. ZHOU Xuqian ,DONG Lei .Comparison of the Effect of Different Enzyme Digestion Methods on Extraction of Porcine Primary Hepatocytes[J].Modern Animal Husbandry Science & Technology ,2024,107(4):53-55.不同酶消化法提取猪原代肝细胞的效果比较周徐倩,董磊*(南京大学,江苏 南京 210023)摘要:猪肝细胞是猪圆环病毒的靶细胞,简单快速地提取猪原代肝细胞对于研究猪圆环病毒病的致病机制具有重要意义。

天冬酰胺合成酶通过促进β-catenin核转位驱动胆管癌转移

天冬酰胺合成酶通过促进β-catenin核转位驱动胆管癌转移

天冬酰胺合成酶通过促进β-catenin 核转位驱动胆管癌转移*褚珍珍1,2, 周栩萱1,2, 刘力豪1, 张鲍欢3△, 姚楠1,2△(1暨南大学基础医学院病理生理学系,广东 广州 510632;2国家中医药管理局病理生理科研实验室,广东 广州510632;3暨南大学基础医学院形态学实验教学中心,广东 广州 510632)[摘要] 目的:检测天冬酰胺合成酶(ASNS )在胆管癌(CCA )中的表达情况,探讨ASNS 在CCA 转移中的作用及其机制。

方法:通过公共数据库分析各肿瘤组织中ASNS 的mRNA 表达;收集CCA 患者病理组织(n =27),构建硫代乙酰胺诱导的大鼠自发CCA 模型和左中位胆管结扎联合二乙基亚硝胺诱导的小鼠自发CCA 模型,通过免疫组化、Western blot 和免疫荧光法检测ASNS 蛋白表达。

采用CCK8、划痕和Transwell 实验检测ASNS 对人CCA 细胞HuCCT1和HCCC -9810增殖、迁移和侵袭的影响。

构建ASNS 稳定敲减的CCA 细胞株HuCCT1shNC 、HuCCT1shASNS 、HCCC -9810shNC 和HCCC -9810shASNS ,通过肝原位种植和尾静脉注射研究ASNS 对CCA 细胞肝内生长和肺转移的影响。

利用公共数据库富集与ASNS 相关的信号通路,并用免疫荧光和Western blot 验证相关分子机制。

结果:无论在人或动物CCA 组织中,ASNS 表达水平均高于癌旁组织(P <0.01)。

ASNS 以酶活性非依赖性方式促进CCA 细胞HuCCT1和HCCC -9810的增殖、迁移与侵袭。

生物信息学分析显示,β-catenin 在ASNS 高表达的CCA 组织中富集,ASNS 通过促进β-catenin 核转位,启动CCA 细胞上皮-间充质转化(EMT )。

β-catenin 抑制剂XAV -939可显著抑制CCA 细胞的侵袭与迁移。

儿童急性髓系白血病的遗传基因异常及其意义

儿童急性髓系白血病的遗传基因异常及其意义

中国小儿血液与肿瘤杂志 2021年 6月第 26卷第 3期 JChinaPediatrBloodCancer,June2021,Vol26,No.3
·131·
2 异常基因在 MRD监测中的作用 21 融 合 基 因 RUNX1RUNX1T1/t(8;21)和 CBFBMYH11/inv(16)/t(16;16)均可用 于 治 疗 后 的 MRD监测 。 [1,811] 诱导或巩固结束后,RTqPCR 检测其转录产物 mRNA拷贝数(ABL做内参),较初 诊时降低 >3个 log者预后良好。究竟在诱导后还 是巩固后降低 >3个 log较有预后意义,视不同方案 而定。如果诱导结束后降低不足 3个 log,在巩固期 间继续降低,直到治疗完全结束后 <初诊时的 4个 log者预后仍好,提示连续监测的重要性。但如果将 RUNX1RUNX1T1和 CBFBMYH11分开统计,可 能 有不同 的 结 果,因 此 需 后 续 更 多 的 研 究[10]。关 于 KMT2A(MLL)基 因 重 排,在 AML 只 有 MLLT3 KMT2A/t(9;11)有详细研究[4],结果显示诱导缓解 后 RTqPCR <10-3和后续监测仍 <10-3复发率低。 BCRABL融合基因在 AML发生率低,用于 MRD监 测的意义尚未有足够的临床验证 。 [11] 以上研究结 果提示在用融合基因检测 MRD方面,连续监测的 重要性,治疗结束后仍低度阳性不影响预后。 22 突变基因 不是所有与 AML相关的突变基因 都适用于 MRD监 测 。 [1,45,1011] 造 血 干 细 胞 基 因 突 变后,获得竞争优势导致克隆造血,但仍有多系分化 和成熟的造血功能不属于白血病细胞,只有在继发 其他突变后才出现分化阻滞和无限增殖,发展为白 血病。随年龄增长干细胞的突变率增加,因此克隆 造血主要见于老年人,儿童少见。较常见的克隆造 血突变基因是编码表观遗传修饰因子的基因 DNMT3A、TET2、IDH、ASXL1,以 及 RNA 剪 接 子 和 Cohesins蛋 白 的 基 因 等。胚 系 突 变 基 因 RUNX1、 GATA2、CEBPA、DDX41和 ANKRD26也 不 适 用 于 MRD检测。与治疗前比较,缓解后突变基因的表达 水平仍没有明显下降,需考虑是克隆造血突变或胚 系突变基因。胚系突变基因可通过检测胚系组织 / 细胞(例如口腔黏膜等)DNA发现。

新员工考试试题

新员工考试试题

新员工考试试题您的姓名: [填空题] *_________________________________一、单选1. 以下哪类患者不属于当前肺癌分子检测的推荐适用人群?() [单选题] *A. IIIB期非小细胞肺癌B. 肺部腺鳞混合癌C. 可手术的肺腺癌D. 小细胞肺癌(正确答案)2. PCR-11基因产品检测突变类型不包括()。

[单选题] *A. RET DNA突变(正确答案)B. KRAS DNA突变C. ROS1 RNA融合D. BRAF DNA突变E. 123. 艾德PD-L1 E1L3N抗体获批哪个药物的伴随诊断?() [单选题] *A. 度伐利尤单抗B. 帕博利珠单抗(正确答案)C. 纳武利尤单抗D. 阿替利珠单抗4. 我司以下哪项检测可使用血液标本进行检测?() [单选题] *A. PD-L1蛋白表达检测B. PCR-9基因检测C. Classic Panel检测D. Master Panel检测(正确答案)5. Classic Panel要求的组织肿瘤细胞含量是() [单选题] *A、10%B、15%C、20%(正确答案)D、30%6. MSI片段分析法伴随诊断的药物是() [单选题] *A. K药B. O药C. 百泽安(正确答案)D. 艾瑞利7. 奥拉帕利在卵巢癌___维持治疗需要检测BRCA基因() [单选题] *A. 一线(正确答案)B. 铂敏感复发C. 铂耐药8. 根据PRIMA研究,卵巢癌中HRD检测较BRCA基因检测可多筛选出___% PARPi获益人群() [单选题] *A. 20%B. 30%(正确答案)C. 50%9. 艾德HRD Complete检测精选____多个SNP位点() [单选题] *A. 15000B. 24000(正确答案)C. 4000010. HRD Complete评分阳性阈值为__分() [单选题] *A. 38B. 42C. 50(正确答案)11.艾德的乳腺癌21基因检测产品是一款基于什么技术平台的检测试剂盒() [单选题] *A. NGSB. ARMS-PCRC. RT-PCR(正确答案)D. FISH12. 除三阴性乳腺癌外,以下哪种亚型乳腺癌患者也应进行BRCA基因检测()[单选题] *A. HER2阳性B. HR阳性/HER2阳性C. HR阳性/HER2阴性(正确答案)D. 都不应该13. 以下方法中,目前最灵敏、准确的评估甲状腺结节良恶性的检查方法是()[单选题] *A. 分子诊断B. 分子诊断+细胞学诊断(正确答案)C. 超声影像学诊断D. 细胞学诊断14.以下哪个产品/产品组合,是2023年甲状腺癌主推产品() [单选题] *A. KNBB. KNBPC. KNB+TH+RET+NTRK(正确答案)D. TC 21基因15. 艾德PD-L1在肺癌判读 时所用的评分方法是?() [单选题] *A. TPS(正确答案)B. CPSC. TCD. IC16. 以下不可用于结直肠癌指导用药的是() [单选题] *A.HER2B.EGFR(正确答案)C.KRASD.BRAF17.ADx PD-L1,在NSCLC中采用()规则判读,在尿路上皮癌中采用()规则判读? [单选题] *都是TPSTPS,CPS(正确答案)CPS,TPS都是CPS18.关于NGS预实验,描述不正确的是()? [单选题] *地区经理为第一责任人流程简单,因此客户提出需求后就可以自行申请试剂(正确答案)每家单位情况不一样,需技术跟客户沟通后才能明确场地和设备是否满足预实验要求预实验前明确预实验目的,不建议客户随口一提试试看就马上申请预实验19.宏石SLAN-96S使用的耗材为? [单选题] *乳白高管乳白矮管透明高管(正确答案)透明矮管磨砂高管磨砂矮管20.肺癌类药物统称为? [单选题] *小分子化合物(正确答案)免疫抑制剂络氨酸激酶抑制剂单克隆抗体PARP抑制剂21. EASY 12提取方法是什么? [单选题] *柱提法磁珠法(正确答案)二、多选1. 以下哪些检测项目可在RNA水平上检测基因融合?() *A. PCR-11基因(正确答案)B. NGS-10基因C. Classic Panel(正确答案)D. Pan 116基因E. Master Panel(正确答案)2. 相比捕获建库的NGS检测项目,PCR多基因与Classic Panel 有哪些共同优势?() *A. 基于RNA检测融合基因更准确(正确答案)B. 报告周期短(正确答案)C. 用于血液检测D. 适合院内开展(正确答案)3. 以下哪些是NGS-10基因试剂盒的优势?() *A. 获批适用癌种最多(正确答案)B. 获批可检基因数最多(正确答案)C. 获批药物伴随诊断数量最多(正确答案)D. 组织检测灵敏度好(正确答案)E. RNA检测融合性能优异4. 以下哪些产品获批了药物伴随诊断?() *A. PCR-11基因(正确答案)B. NGS-10基因(正确答案)C. Super-ARMS EGFR(正确答案)D. PD-L1抗体(正确答案)E. Master Panel5. 2023年KNBP的主要目标科室是() *A. 肿瘤内科(正确答案)B. 胃肠外科(正确答案)C. 普外科D. 大肠外科6. 国内NMPA批准的结直肠癌适应症的公司和产品有() *A. 艾德生物:KNBP联合检测试剂盒(正确答案)B.艾德生物:10基因突变检测试剂盒(正确答案)C. 臻悦生物:KNBP检测试剂盒D. 思路迪:KNBP检测试剂盒7. KRAS需要检测的外显子是() *A.2号外显子(正确答案)B.3号外显子(正确答案)C.4号外显子(正确答案)D.5号外显子8. Classic Panel的产品优势有() *A.准:与伴随诊断产品准确性一致率高(正确答案)B.全:检测靶点全,变异类型全(正确答案)C.快:专利技术缩短建库时间,院内3天可出报告(正确答案)D.新:数据库时时更新,报告精准易读(正确答案)9. BRCA1/2基因检测在卵巢癌临床诊疗中的意义包括() *A. 判断预后(正确答案)B. 指导治疗(正确答案)C. 遗传筛查(正确答案)D.指导手术10. 艾德HRD Complete的检测内容包括() *A. BRCA1/2基因(正确答案)B. MMR基因C. HRR通路其他基因D. HRD 评分(正确答案)11. HRD Complete GSS评分检测_____三种基因组不稳定形式() *A. LCN(正确答案)B. TCN(正确答案)C. SCN(正确答案)12. 所有的乳腺癌患者都应做BRCA1/2突变检测,尤其以下哪几类乳腺癌患者一定要做BRCA1/2检测() *A. 发病年龄<45岁(正确答案)B. 有乳腺癌家族史(正确答案)C. 三阴性乳腺癌患者(正确答案)D. 双侧乳腺癌患者(正确答案)13. . 进行BRCA1/2基因检测,其意义包括() *A. 早期乳腺癌患者BRCA基因突变可指导含铂化疗药物、PARP抑制剂使用(正确答案)B. 晚期乳腺癌患者BRCA基因突变可指导含铂化疗药物、PARP抑制剂使用(正确答案)C. 早期乳腺癌患者BRCA基因突变可指导术式选择(正确答案)D. 健康人群可提示遗传性乳腺癌发病风险(正确答案)14. 使用以下哪种类型的样本,可以做到使分子诊断与细胞学诊断同步开展() *A. 穿刺样本洗脱液(正确答案)B. 独立穿刺物(正确答案)C. 细胞蜡块D. 手术样本15. 纵观甲状腺癌的患者流,艾德产品首推的卖点为术前辅助良恶性鉴别,该节点上BRAF单点检测需升级为多基因检测;除BRAF外,以下哪些基因可以在该节点上推广() *A. TERT(正确答案)B. EGFRC. NRAS(正确答案)D. KRAS(正确答案)16. 艾德PD-L1能在哪些平台使用?() *A. 徕卡 BOND平台(正确答案)B. 罗氏 Ventana平台(正确答案)C. DAKO LINK48平台(正确答案)D. 艾德STAR平台(正确答案)17. 艾德PD-L1与迈杰PD-L1比较,不同之处主要体现在哪些?() *A. 获批适应症不同(正确答案)B. 进行比对的克隆号不同(正确答案)C. 药效试验所选用的药物不同(正确答案)D. 克隆号不同18. 艾德目前在仪器平台的布局包含哪些仪器?() *A. PCR仪(正确答案)B.全自动核酸提取仪(正确答案)C.高通量测序仪(正确答案)D.免疫组化染色仪(正确答案)19. 关于乳腺癌各产品的检测机会,以下描述正确的是() *A. BRCA、HRR可以推广至HER2-乳腺癌患者,术后辅助治疗阶段(正确答案)B. BRCA、HRR可以推广至HER2-乳腺癌患者,晚期一线治疗阶段(正确答案)C. 21基因可以推广至HR+/HER2-乳腺癌患者,术后辅助治疗阶段(正确答案)D. PIK3CA可以推广至HER2+和HR+/HER2-乳腺癌患者(正确答案)20. EASY 12的优势主要体现在哪些方面?() *A. 可进行DNA与RNA的共提(正确答案)B. 可处理大体积血浆样本(正确答案)C. 可提取全血DNA(正确答案)D. 通量很大E. 可以全自动运行操作简便(正确答案)21.ADx PD-L1产品已验证可使用机型包括()? * Leica Bond Max(正确答案)迈新DAKO AutoStainer Link48(正确答案)Ventana BenchMark ULTRA(正确答案)22.关于ADx PD-L1抗体以下说法正确的是()? *是O药的伴随诊断试剂保存温度是4度(正确答案)属于兔源(正确答案)具备三类注册证(正确答案)23.IHC常见的染色模式包括()? *膜染(正确答案)胞浆染色(正确答案)核染(正确答案)核染+质染(正确答案)24.IHC预实验申请一般包括()? *PD-L1(正确答案)IgG(正确答案)核酸提取试剂预实验配套试剂(正确答案)25.二代测序的技术特点包括()? *已知突变和未知突变均能检测(正确答案)一次可检测多个至上千个基因(正确答案)操作简单,1天即可出报告可以对突变进行定量检测(正确答案)26.HANDLE建库相对于杂交捕获建库的优势有()? *操作简单,步骤更少,人员要求相对较低(正确答案)实验周期更短,最快3天出报告(正确答案)设备要求少,不需要超声打断仪,浓缩仪等昂贵设备(正确答案)目前可以应用于大panel的检测27.我司NGS产品目前可应用于哪些二代测序平台()? * Illumina(正确答案)LifeADx-SEQ200 Plus(正确答案)适用于华大平台的所有机型28.Illumina平台测序仪在医院最常见到的有()? *NextSeq 500/CN500/550Dx(正确答案)MiSeqDx/MiSeq(正确答案)MiniSeq(正确答案)ADx-SEQ200 Plus29.NGS实验室相对于PCR实验室,其要求是()? *房间更多(HANDLE一般5间,杂交捕获8-9间)(正确答案)设备更多(正确答案)区域更大(正确答案)要求更高(正确答案)30.核酸包括? *单链结构的RNA(正确答案)双链结构的DNA(正确答案)双链结构的RNA蛋白质染色体31.市面上常见的qPCR仪是? *MX3000P(正确答案)ABIQ5(正确答案)ABI7500(正确答案)LC480(正确答案)SLAN 96S(正确答案)CFX 9632.以下哪些不是临床PCR实验室设计的一般原则()? *各区合并(正确答案)单向通道不可逆向因地制宜方便工作33.使用乳白高管的仪器为()? *MX3000P(正确答案)ABI7500(正确答案)LightCycler 480 I宏石34.以下哪些PCR仪需要辅助器? *ABI7500(正确答案)3000P罗氏480(正确答案)CFX96宏石35. EASY 12目前可以从哪些类型的样本中提取核酸? *FFPE手术样本(正确答案)血浆样本(正确答案)全血样本(正确答案)FFPE穿刺样本(正确答案)新鲜组织1.艾德PD-L1抗体需要稀释后使用 [判断题] *对错(正确答案)2.ADx PD-L1不支持手工染色 [判断题] *对(正确答案)错3.科室内有DAKO AutoStainer Link48和Ventana BenchMark ULTRA平台,优先选择后者进行预实验 [判断题] *对错(正确答案)4.NGS预实验成本集中在测序试剂,一般情况下预实验仅提供一套测序试剂 [判断题] *对(正确答案)错5.血液白细胞检测的是胚系变异,肿瘤组织检测的是体细胞变异 [判断题] *对(正确答案)错6.服务器的功能是做数据储存及分析,因此各厂家的服务器都是通用的 [判断题] *对错(正确答案)7.BRAF试剂盒是大包装试剂,上机时需要根据仪器选择相匹配的耗材,如安捷伦3000P为乳白矮管 [判断题] *对错(正确答案)8.基因是具有遗传功能的NDA片段 [判断题] *对(正确答案)错9.MSI是微卫星不稳定 [判断题] *对(正确答案)错。

利用大肠杆菌全细胞催化赖氨酸发酵液生产1,5-戊二胺

利用大肠杆菌全细胞催化赖氨酸发酵液生产1,5-戊二胺

2017年第36卷第5期 CHEMICAL INDUSTRY AND ENGINEERING PROGRESS·1843·化 工 进展利用大肠杆菌全细胞催化赖氨酸发酵液生产1,5-戊二胺齐雁斌,马伟超,陈可泉(南京工业大学生物与制药工程学院,江苏 南京 211816)摘要:1,5-戊二胺是一种具有生物活性的生物胺。

赖氨酸脱羧酶可以催化L-赖氨酸生产1,5-戊二胺。

为了减少生产成本,本文利用大肠杆菌AST1以赖氨酸发酵液作为底物进行全细胞催化生产1,5-戊二胺。

研究转化pH 、菌体浓度、转化温度、磷酸吡哆醛(PLP )添加量以及不同酸种类对转化的影响,并对菌体的重复利用性进行了研究。

在最优条件下:pH6.8、转化温度37℃、PLP 添加量0.1mmol/L 、菌体浓度(DCW )2.5g/L ,用乙酸来调节转化过程pH ,可以转化含有赖氨酸123.8g/L 的发酵液,得到含有86.18g/L 戊二胺的转化液,转化率可达到99.61%。

并且菌体在赖氨酸发酵液中重复利用5次的情况下转化率可以达到50%以上,重复利用性明显比在赖氨酸溶液中转化时强,这极大程度地节约了生产成本,为1,5-戊二胺连续工业化生产打下了基础。

关键词:1,5-戊二胺;赖氨酸发酵液;全细胞转化;工业化生产中图分类号:TQ033 文献标志码:A 文章编号:1000–6613(2017)05–1843–05 DOI :10.16085/j.issn.1000-6613.2017.05.0361,5-pentanediamine production by using Escherichia coli whole-cellbiocatalysis lysine fermentation liquidQI Yanbin ,MA Weicao ,CHEN Kequan(Biotechnology and Pharmaceutical Engineering ,Nanjing University of Technology ,Nanjing 211816,Jiangsu ,China )Abstract:1,5-pentanediamine is a bioactive biogenic amine. L-lysine decarboxylase can catalyze with L-lysine to produce 1,5-pentanediamine. To reduce the production cost ,whole cell catalytic production of 1,5-pentanediamine was outperformed using Escherichia coli AST1 and with lysine fermentation broth as the substrate. The effects of transformation pH ,cell concentration ,transformation temperature ,PLP addition amount ,and different kinds of acid on the transformation and the reusability of the cells were investigated. At the optimal condition ,0.1mmol/L PLP ,2.5g/L DCW and pH as 6.8,37℃,86.18g/L of 1,5-pentanediamine was obtained by transforming the fermentation broth containing 123.8 g/L L-lysine ,and adjusting the pH using the acetic acid during conversion process. Furthermore ,the cells can be reused five times and the substrate conversion rate maintained above 50% in the lysine fermentation broth. The reusability was better than that in the lysine solution ,which greatly reduces the production cost and lays a foundation for 1,5-pentanediamine commercial production. Key words :1,5-pentanediamine ;lysine fermentation liquid ;whole-cell biocatalysis ;commercial process1,5-戊二胺(1,5-pentanediamine ,简称戊二胺),即尸胺,是生物体内广泛存在的具有生物活性的含氮碱,为蛋白质腐败时赖氨酸在脱羧酶作用下发生脱羧反应时生成的产物。

Clec9A介导的体内坏死细胞清除机制研究进展

Clec9A介导的体内坏死细胞清除机制研究进展

Clec9A介导的体内坏死细胞清除机制研究进展①晏黎黄伟全紫瑶②崔天盆(湖北中医药大学附属武汉市中西医结合医院检验科,武汉430022)中图分类号R392.12文献标志码A文章编号1000-484X(2021)12-1517-04[摘要]机体在病毒感染、肿瘤等病理因素下产生的大量坏死细胞需要细胞毒性T淋巴细胞(CTL)的靶向杀伤作用来清除。

人外周血BDCA3+树突状细胞上的Clec9A能特异性识别与结合坏死细胞暴露的纤维状肌动蛋白(F-actin),激活胞内脾酪氨酸激酶Syk。

Clec9A作为F-actin的受体,不仅内吞坏死细胞,同时将坏死细胞相关抗原交叉提呈至CD8+T细胞,活化CTL,启动机体获得性免疫应答。

CTL释放的穿孔素及颗粒酶特异性杀伤靶细胞,导致体内感染细胞或肿瘤细胞进一步被清除。

因此,Clec9A在机体抗病毒感染、肿瘤治疗中具有潜在的应用前景。

[关键词]C型凝集素9家族A成员;纤维状肌动蛋白;坏死细胞;交叉提呈Research progress on Clec9A-mediated mechanism of phagocytosis necrotic cells in vivoYAN Li,HUANG Wei,QUAN Zi-Yao,CUI Tian-Pen.Department of Laboratory Medicine,Wuhan Traditional Chinese and Western Medicine Hospital,Hubei University of Chinese Medicine,Wuhan430022,China [Abstract]A large number of necrotic cells produced by the pathological factors such as virus infection and tumor,which need to be clearanced by the targeted killing effect of cytotoxic T lymphocytes(CTL).C-type lectin domain family9A(Clec9A,or DNGR-1)on human blood BDCA3+dendritic cells can specifically identify and bind F-actin exposed by necrotic cells,activate the spleen tyro‑sine-based kinase(Syk)pathway.As the receptor of F-actin,Clec9A not only phagocytosis necrotic cells,but also cross-presents necrosis-related antigens to CD8+T cells,which results in the activation CTL and initiates the adaptive immune response.Perforin and granzyme released by CTL further damage infected tissue cells or tumor cells,leading to apoptosis and necrosis of the injured cells and further clearance.Therefore,Clec9A has a potential application prospect in anti-viral,tumor therapy.[Key words]Clec9A;F-actin;Necrotic cells;Cross-presentation恶性肿瘤由于生长迅速,肿瘤中央部位血液供应相对不足,易导致肿瘤细胞发生坏死。

生物免疫学英文词汇汇总学习---

生物免疫学英文词汇汇总学习---

生物免疫学英文词汇汇总学习---work Information Technology Company.2020YEAR医学免疫学英中文词汇Aaccessibility易接近性acetylcholine,Ach乙酰胆碱acquired immune deficiency syndrome,AIDS 获得性免疫缺陷综合征(艾滋病)acquired tolerance获得性免疫耐受activation-induced cell death,AICD,活化诱导的细胞凋亡active immunotherapy 主动免疫疗法acute phase protein,APP急性期蛋白acute rejection急性排斥反应acute vascular rejection,AVR 急性血管性排斥adaptive immune system适应性免疫系统 adaptiveimmunity适应性免疫adenosinedeaminase,ADA腺苷脱氨酶adhesionmolecule,AM黏附分子adjuvant佐剂adoptiveimmunity过继免疫adultthymectomy,AT成年胸腺切除术affinity亲和力affinitymaturation(抗体)亲和力成熟agglutination凝集反应alkalinephosphatase,AP碱性磷酸酶allergen变应原allergicinflammation,AI变态反应炎症alloantigen同种异型抗原allograft同种异基因移植allotype同种异型alpha-fetoprotein,√廿P甲胎球蛋白alternativepathway旁路(替代)途径anaphylatoxin过敏毒素anaphylaxis过敏反应ankylosingspondylitis,AS强直性脊柱炎antibodydependent cell-mediatedcytotoxicity,ADCC抗体依赖性细胞介导的细胞毒作用antibody,Ab抗体,antigenpresentation抗原提呈antigenpresenting cell,APC抗原提呈细胞,antigen,Ag抗原,antigen-bindingfragment,Fab抗原结合片段,antigen-bindingsite抗原结合部位,antigenicdeterminant,AD抗原决定簇antigenic valence抗原结合价,antigenicity抗原性,anti-idiotype,Aid抗独特型anti—infectionimmunity抗感染免疫antiserum抗血清antitoxin抗毒素apoptosis细胞凋亡artificial activeimmunization人工主动免疫artificial antigen人工抗原artificial passiveimmunization人工被动免疫ataxiatelangiectasia,AT 毛细血管扩张性共济失调综合征2atopy特应性attenuated vaccine减毒活疫苗autoantigen 自身抗原autograft 自体移植autoimmune disease 自身免疫病autoimmunity自身免疫avidin亲和素(抗生物素蛋白) avidity亲合力azoprotein偶氮蛋白Bp barrel p桶状p lysin乙型溶素B cell receptor,BCR B细胞受体basophil嗜碱粒细胞Bence-Jones protem本周蛋白bbfunctionanibody,B{Ab双功能抗体Bioinformaties生物信息学biologicalresponsemodifier,BRM生物应答调节剂biotin生物素,biotin-avidinsystem,BAS生物素一亲和素系统bi-specificantibody,BsAb双特异抗体bone marrow骨髓bovine gammaglobulin,BGG牛丙种球蛋白bradykinin缓激肽bursa of Fabricius法氏囊bursa or bonemarfowdependentlymphocyte法氏囊或骨髓依赖的淋巴细胞(B细胞)CC reactionprotein,CRP C反应蛋白C1 inhibitor,C1INH C1抑制物C3b inactivatorC3b灭活因子(I因子)CA bindingprotein,CAbpCA结合蛋白Cadherin钙黏蛋白Calnexin钙联蛋白carcinoembryonicantigen,CEA癌胚抗原carrier载体carrier effect载体效应Caspase半胱天冬蛋白酶CD40 ligand,CD40L CIM0配体cell surfacemarker细胞表面标记cellular rejection细胞性排斥反应central immuneorgan中枢免疫器官central tolerance中枢耐受centroblast生发中心母细胞chemokine趋化因子chemotaxis趋化性chimeric antibody嵌合抗体chronic rejection慢性排斥反应class 11-associatedinvariant chainpeptide,CLIP Ⅱ类相关的恒定链肽段classical pathway经典途径clonal anergy克隆无能clonal deletion克隆清除clonal selectiontheory克隆选择学说3cluster of differentiation,CD分化群codominance共显性collagen,CA胶原蛋白colony forming unit-culture,CFU-C体外培养集落形成单位colony forming unit-spleen,CFU-S 脾集落形成单位colony stimulating factor,CSF集落刺激因子committed stem cell定向干细胞common antigen 共同抗原complement dependent cytotoxicity,CDC 补体依赖的细胞毒complement receptor,CR补体受体complement system补体系统complement,C补体complementaritydeterminingregion,CDR互补决定区complete antigen完全抗原concanavalin A,ConA刀豆蛋白Aconformationaldeterminant构象决定簇conjugate vaccine结合疫苗constantregion,C区恒定区Coombs test抗球蛋白试验coreceptor共受体cortex皮质区co-stimulatorymoleculereceptor,CMR协同刺激分子受体co-stimulatorymolecule,CM协同刺激分子cross-reaction交叉反应crystallizablefragment,Fe可结晶片段CTL antigen-4,Cn。

clec3b分子量

clec3b分子量

clec3b分子量Clec3b分子量是指c-type凝集素域家族3B蛋白的分子量。

Clec3b 是一种跨膜蛋白,属于c-type凝集素家族。

该蛋白在免疫反应和细胞间相互作用中起着重要的作用。

本文将重点介绍Clec3b的分子量以及其在生物学中的功能。

Clec3b的分子量为约25千道尔顿(kDa)。

它是一种单亲型膜蛋白,由一个细胞外的c-type凝集素域和一个细胞内的短肽序列组成。

Clec3b在多种细胞类型中表达,包括树突状细胞、巨噬细胞和内皮细胞等。

Clec3b蛋白在免疫反应中起着重要的作用。

它可以与病原体表面的糖基结构特异性结合,从而介导病原体的识别和清除。

研究发现,Clec3b能够与细菌、真菌和病毒等多种病原体相互作用,参与机体对它们的免疫应答。

这种特异性结合是由于Clec3b细胞外的c-type凝集素域与病原体表面的糖基结构之间的相互作用。

除了在免疫反应中的作用外,Clec3b还参与细胞间的相互作用。

研究发现,Clec3b在细胞黏附和细胞迁移过程中起着重要的调控作用。

它可以通过与其他细胞表面的配体结合,参与细胞间信号传导和细胞黏附的调节。

这些细胞间相互作用对于胚胎发育、组织修复和免疫细胞的功能发挥都至关重要。

Clec3b还与肿瘤的发生和发展相关。

研究发现,Clec3b的表达在某些肿瘤中显著上调,与肿瘤的侵袭和转移能力密切相关。

通过调节细胞的迁移和侵袭能力,Clec3b参与了肿瘤细胞的转移和扩散过程。

因此,Clec3b可能成为肿瘤治疗的潜在靶点。

总结起来,Clec3b是一种重要的膜蛋白,其分子量约为25kDa。

它在免疫反应中通过与病原体结合介导病原体的识别和清除。

同时,它还参与细胞间的相互作用,调控细胞黏附和迁移过程。

此外,Clec3b在肿瘤发生和发展中也起着重要的调控作用。

对于进一步了解Clec3b的功能及其在疾病中的作用,还需要进一步的研究。

Nature亮点丨改善化疗效果或许需只要补充一点组氨酸

Nature亮点丨改善化疗效果或许需只要补充一点组氨酸

Nature亮点丨改善化疗效果或许需只要补充一点组氨酸责编丨迦溆甲氨喋呤(methotrexate),图片来源于/甲氨喋呤(methotrexate)是一种抗肿瘤药物,常用于治疗白血病、淋巴瘤、骨肉瘤等。

作为一种叶酸类似物,甲氨喋呤的作用机理主要是进入机体后可以与叶酸还原酶和二轻叶酸还原酶结合,与叶酸产生竞争性的拮抗作用,抑制四氢叶酸的合成。

四氢叶酸可以参与核酸的合成,对细胞增殖具有重要作用,因此拮抗叶酸能够抑制细胞的生长,当然也可以抑制肿瘤的生长【1】。

另一方面,作为临床上的抗肿瘤化疗药物,甲氨喋呤需要大量使用,此时具有较大的毒副作用,而且作用效果在某些情况下也有限,具有药物抵抗性【2】。

那么能否通过全基因组筛选的方法找到能提高甲氨蝶呤敏感性的基因呢?7月11日,来自MIT/Whitehead生物医学研究所的David M. Sabatini课题组在Nature上发表了题为Histidine catabolism is a major determinant of methotrexate sensitivity的论文,利用CRISPR-Cas9技术对经过甲氨蝶呤处理的白血病细胞进行筛选,找到了调控甲氨蝶呤敏感性的基因FTCD(formimidoyltransferase cyclodeaminase,亚胺甲基转移酶环化脱氨酶),敲除FTCD后,发现原本对甲氨蝶呤敏感的白血病细胞丧失了敏感性,由于该基因参与组氨酸的分解代谢调控过程,进而揭示了组氨酸的分解代谢过程调控了肿瘤细胞对甲氨蝶呤的敏感性,这对于临床上提升甲氨蝶呤的治疗肿瘤的效果具有重要意义。

在这项研究中,研究人员从42种白血病细胞系中选取了对甲氨蝶呤最为敏感的人的红白血病细胞系HEL(human erythroleukemia cell line),然后用CRISPR-Cas9技术进行正向筛选,最终筛选的结果中有两个最优选择基因:一个是编码叶酸转运蛋白的SLC19A1,另一个是参与组氨酸分解代谢的FTCD。

草珊瑚总黄酮对小鼠血脂的影响

草珊瑚总黄酮对小鼠血脂的影响

草珊瑚总黄酮对小鼠血脂的影响吉宁【期刊名称】《山地农业生物学报》【年(卷),期】2012(31)3【摘要】通过建立小白鼠高血脂模型,提取分离草珊瑚中的总黄酮,喂食模型小白鼠,测定小白鼠血清中的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C),探讨草珊瑚中的总黄酮对小鼠血脂的影响.结果表明:草珊瑚总黄酮各组小鼠血清中TG、TC、LDL -C的含量显著低于模型组(P<0.05),说明草珊瑚总黄酮有抗高血脂症的作用,高剂量降脂效果接近洛伐他丁.%The total flavonoids were extracted and separated from Sarcandrae glabra, subsequently, it was used to feed the model mice of hyperlipidemia. The effect of total flavonoids on mouse blood-fat content was investigated by quantification of mouse serum triglyceride (TG) , total cholesterol (TC) , and low density lip-oprotein(LDL-C). The results showed that compared with the model group, treatment of total flavones gave significantly reduction in the contents of TG, TC, and LDL-C (P <0.05), indicating the total flavonoids of Sarcandrae glabra has anti-hyperlipidemia effect, and use of high dosage may demonstrate the close lipid-low-ering effect to lovastatin.【总页数】4页(P268-270,278)【作者】吉宁【作者单位】贵州大学生命科学学院,贵州贵阳 550025【正文语种】中文【中图分类】R963【相关文献】1.不同逆境胁迫条件对草珊瑚总黄酮含量的影响 [J], 苏虎;周春丽2.山荆子叶总黄酮对糖尿病小鼠血糖、血脂的作用 [J], 丁传波;刘璐璐;赵婷;董岭;李佳琪;王洲婷;韩佳彤;郑毅男;刘文丛3.镰形棘豆总黄酮对糖尿病KKAy小鼠血脂及瘦素、脂联素、抵抗素的影响 [J], 杨丽霞;王志程;李雪英;张邦能;郭敏;姜良恩;刘铜华4.金花葵总黄酮对小鼠血脂影响的实验研究 [J], 雷波5.柿叶总黄酮对糖尿病小鼠降血糖降血脂作用及其机制研究 [J], 高永峰;高允生;辛晓明因版权原因,仅展示原文概要,查看原文内容请购买。

相关主题
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Hemolytic C-Type Lectin CEL-III from Sea Cucumber Expressed in Transgenic Mosquitoes Impairs Malaria Parasite DevelopmentShigeto Yoshida1*,Yohei Shimada1,Daisuke Kondoh1,Yoshiaki Kouzuma2,Anil K.Ghosh3,Marcelo Jacobs-Lorena3, Robert E.Sinden41Division of Medical Zoology,Department of Infection and Immunity,Jichi Medical University,Tochigi,Japan,2College of Agriculture,Ibaraki University,Ami-machi, Inashiki-gun,Ibaraki,Japan,3Department of Molecular Microbiology and Immunology,Malaria Research Institute,Johns Hopkins School of Public Health,Baltimore, Maryland,United States of America,4Infection and Immunity Section,Division of Cell and Molecular Biology,Imperial College London,South Kensington,London,United KingdomThe midgut environment of anopheline mosquitoes plays an important role in the development of the malaria ing genetic manipulation of anopheline mosquitoes to change the environment in the mosquito midgut may inhibit development of the malaria parasite,thus blocking malaria transmission.Here we generate transgenic Anopheles stephensi mosquitoes that express the C-type lectin CEL-III from the sea cucumber,Cucumaria echinata,in a midgut-specific manner.CEL-III has strong and rapid hemolytic activity toward human and rat erythrocytes in the presence of serum.Importantly,CEL-III binds to ookinetes,leading to strong inhibition of ookinete formation in vitro with an IC50of15nM.Thus,CEL-III exhibits not only hemolytic activity but also cytotoxicity toward ookinetes.In these transgenic mosquitoes,sporogonic development of Plasmodium berghei is severely impaired.Moderate,but significant inhibition was found against Plasmodium falciparum.To our knowledge,this is the first demonstration of stably engineered anophelines that affect the Plasmodium transmission dynamics of human malaria.Although our laboratory-based research does not have immediate applications to block natural malaria transmission,these findings have significant implications for the generation of refractory mosquitoes to all species of human Plasmodium and elucidation of mosquito–parasite interactions.Citation:Yoshida S,Shimada Y,Kondoh D,Kouzuma Y,Ghosh AK,et al.(2007)Hemolytic C-type lectin CEL-III from sea cucumber expressed in transgenic mosquitoes impairs malaria parasite development.PLoS Pathog3(12):e192.doi:10.1371/journal.ppat.0030192IntroductionMalaria,transmitted by anopheline mosquitoes,is among the worst health problems in the world,killing1–2million people every year,mostly African ck of an effective vaccine and the emergence of Plasmodium strains resistant to many existing anti-malarial drugs have aggravated this situation.Therefore,the control of vector competence has become a more important target in malaria intervention. Recent advances in genetic engineering of anopheline mosquitoes have raised hopes for their use as new strategies for malaria control,also the provision of powerful tools for investigating mosquito-parasite interactions.We and others have characterized tissue-specific promoters that drive robust expression of transgenes in the midgut[1,2],hemocoel[3], and salivary glands[4].The next challenge is to identify ‘‘effector’’molecules to inhibit development of malaria parasites without competitive cost to the mosquito.To date, several effector molecules have been identified(e.g.,single-chain antibody fragments directed against parasite ligands [5,6],the dodecapeptide SM1[7],PLA2[8],a cecropin-like peptide[9],and the Vida3peptide[10];(see reviews[11,12]). Of these,transgenic mosquitoes expressing either SM-1or PLA2in a midgut-specific manner were less able to support transmission of the rodent parasite P.berghei[13,14].How-ever,the SM1transgenic mosquito was not resistant to the human malaria parasite P.falciparum(M.Jacobs-Lorena, unpublished observations),and the PLA2transgenic mosqui-to was significantly lessfit than the wild-type[15].In those transgenic mosquitoes generated so far,no single effector molecule has exhibited a‘‘non-sporozoite’’phenotype in the salivary glands,i.e.,complete Plasmodium transmission block-ade.Therefore,other effector molecules and/or mechanisms are required to generate a transgenic mosquito that is bothfit and refractory to all species and strains of human Plasmodium. Transmission of malaria parasites is absolutely dependent on availability of competent mosquito vectors.Development of Plasmodium in the mosquito begins with ingestion of an infectious blood meal containing gametocytes from a verte-brate host[16].In the mosquito midgut lumen,female and male gametocytes mature into gametes after exposure to environmental and mosquito-specific factors.These include a drop in temperature of58C and exposure to xanthurenic acid [17].A signal transduction cascade results in the release of Editor:Kenneth Vernick,University of Minnesota,United States of AmericaReceived April16,2007;Accepted October30,2007;Published December21, 2007Copyright:Ó2007Yoshida et al.This is an open-access article distributed under the terms of the Creative Commons Attribution License,which permits unrestricted use,distribution,and reproduction in any medium,provided the original author and source are credited.Abbreviations:AsCPA,Anopheles stephensi carboxypeptidase A;AgCPA,Anoph-eles gambiae carboxypeptidase A;C-type,Ca2þ-dependent;HE,hematoxylin and eosin;TBp,transmission blockade of prevalence;TBi,transmission blockade of intensity*To whom correspondence should be addressed.E-mail:shigeto@jichi.ac.jpcalcium in the cytoplasm of the activated gametocyte, initiating development and its escape from the erythrocyte [18].After fertilization,the zygote matures into a motile ookinete.Anopheline mosquitoes rapidly concentrate the contents of the blood meal1.5-to2-fold,resulting in highly viscous gut content.Although little is known about the influence of these changes,we postulated that changes to the midgut environment could inhibit parasite development.We chose to express the CEL-III lectin from the sea cucumber, Cucumaria echinata.CEL-III is a Ca2þ-dependent(C-type)lectin, that exhibits strong hemolytic and cell-dependent activity[19] as well as cytotoxicity toward some cultured cell lines[20]by forming ion-permeable pores in target cell membranes through oligomerization after binding to carbohydrate chains on the cell surface[21,22].Furthermore,synthetic peptides derived from the C-terminal hydrophobic region of CEL-III exhibit strong activity against Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis[23].Here we show that CEL-III strongly inhibits ookinete formation in vitro,and transgenic mosquitoes expressing CEL-III in the midgut significantly inhibit oocyst formation and sporozoite production,not only of P.berghei but also P. falciparum.To our knowledge,this is thefirst demonstration of stably engineered anophelines in which the reduction of vectorial capacity transcends Plasmodium species.ResultsHemolytic and Hemagglutination Activities of CEL-III Are Directed Toward Human and Rat Erythrocytes,but Not Mouse ErythrocytesCEL-III has strong Ca2þ-dependent hemolytic activity toward human and rabbit erythrocytes,but shows only weak hemagglutination of chicken and horse erythrocytes[24].This species-specific hemolysis is due to the binding of CEL-III to specific carbohydrate receptors on the erythrocyte surface. We examined whether CEL-III has hemolytic and hemagglu-tination activities toward mouse and rat erythrocytes as hosts for the rodent malaria parasite P.berghei.Figure1A and1BFigure1.Hemolytic and Hemagglutination Activities of CEL-III toward Human,Mouse,and Rat Erythrocytes(A)Serial2-fold dilutions of CEL-III were mixed with human,mouse,or rat erythrocytes in V-shaped microtiter plate wells.Samples were incubated in the absence(À)or presence(þ)of5%FBS.Hemolysis was examined visually after incubation for1h at room temperature.(B)Hemolytic activity toward human,mouse,and rat erythrocytes was expressed as the absorbance at550nm resulting from release of hemoglobin.(C)Serial2-fold dilutions of CEL-III were mixed with human,mouse,or rat erythrocytes in V-shaped microtiter plate wells.Samples were incubated in the presence of10%Dextran4.Agglutination was examined visually after incubation for1h at room temperature.(D)CEL-III was added to mouse(panels1and2)or rat erythrocytes(panels3and4),and bound CEL-III was detected with FITC-labeled anti-mouse IgG following mouse anti-CEL-III antibody by fluorescence microscopy.Panels1and3,phase contrast;panels2and4,FITC.Scale bars are10l m. doi:10.1371/journal.ppat.0030192.g001Author SummaryMalaria is arguably the most important vector-borne diseaseworldwide,affecting300million people and killing1–2millionpeople every year.The lack of an effective vaccine and theemergence of the parasites’resistance to many existing anti-malarialdrugs have aggravated the situation.Clearly,development of novelstrategies for control of the disease is urgently needed.Mosquitoesare obligatory vectors for the disease and inhibition of parasitedevelopment in the mosquito has considerable promise as a newapproach in the fight against malaria.Based on recent advances inthe genetic engineering of mosquitoes,the concept of generatinggenetically modified(GM)mosquitoes that hinder transmission byeither killing or interfering with parasite development is a potentialmeans of controlling the disease.To generate these GM mosquitoes,the authors focused on a unique lectin isolated from the seacucumber,which has both hemolytic and cytotoxic activities,as ananti-parasite effector molecule.A transgenic mosquito expressingthe lectin effectively caused erythrocyte lysis in the midgut afteringestion of an infectious blood meal and severely impaired parasitedevelopment.This laboratory-acquired finding may provide signifi-cant implications for future malaria control using GM mosquitoesrefractory to the parasites.shows that the hemolytic activity of CEL-III was strong toward human and rat erythrocytes at low concentrations (IC 50¼0.3and 0.8l g/ml,respectively)in the presence of 5%fetal bovine serum (FBS:a source of Ca 2þ),whereas there was no hemolytic activity toward mouse erythrocytes.Weak hemolytic activity was observed against human and rat erythrocytes even in the absence of FBS.Similarly,CEL-III exhibited strong hemag-glutination activity toward human and rat erythrocytes,but not toward mouse erythrocytes (Figure 1C).Fluorescent microscopic studies also confirmed that CEL-III bound to rat erythrocytes with numerous punctuate dots distributed throughout the cells,whereas no signals were detected in mouse erythrocytes (Figure 1D).These results suggest that carbohydrate chains on the mouse and rat erythrocyte surface may differ.In Vitro Effect of CEL-III on Ookinete DevelopmentIt has been reported that CEL-III is cytotoxic toward some cultured cell lines as well as toward erythrocytes [20].Therefore,we investigated the effect of CEL-III on ookinete development in vitro.At first,CEL-III was added to cultured ookinetes in the absence of Ca 2þ.Figure 2A shows that bound CEL-III was observed as small punctuate dots distributed throughout the ookinete (similar the binding of CEL-III to rat erythrocytes as shown in Figure 1D),whereas no signals were detected in the ookinete without CEL-III.Next,CEL-III was incubated with gametocytes in vitro and the number of ookinetes was determined 24h later.Figure 2B shows that CEL-III (10l g/ml)inhibited ookinete development by approximately 95%.This inhibition was dose-dependent,with an IC 50of approximately 15nM.CEL-III Is Expressed in the Midgut of Transgenic MosquitoesTo express CEL-III in the A.stephensi midgut,we made a pAgCP-CEL-III gene cassette consisting of the promoter,59-UTR,and signal peptide from the A.gambiae carboxypepti-dase A (AgCPA )gene [1]linked to the coding sequence of the CEL-III gene that lacked signal peptide sequence and the anopheles trypsin 1(Antryp1)putative terminator region (Figure 3A).This gene cassette was inserted into pMinos-EGFP-RfA-F to constructpMinos-EGFP-carboxypeptidaseP-Figure 2.Binding of CEL-III to Ookinetes Inhibits Parasite Development In Vitro(A)Binding of CEL-III to ookinetes.CEL-III was added to cultured ookinetes purified from P.berghei –infected mouse blood.Bound CEL-III was detected with FITC-labeled anti-mouse IgG following mouse anti-CEL-III antibody by fluorescence microscopy (panels 1and 2)(CEL-III (þ)).As a negative control,ookinetes were incubated with FITC-labeled anti-mouse IgG following mouse anti-CEL-III antibody without CEL-III (panels 3and 4)(CEL-III (À)).Panels 1and 3,phase contrast;panels 2and 4,FITC.Arrows indicate cultured ookinetes.Scale bars are 10l m.(B)Effect of CEL-III on ookinete development in vitro.P.berghei –infected mouse blood was cultured for ookinetes for 24h at 198C.CEL-III was added at initiation of the culture at various concentrations.Data are expressed as number of ookinetes relative to medium alone (100%).Results are the mean of two independent experiments,and bars represent standard errors of the mean.doi:10.1371/journal.ppat.0030192.g002Figure 3.Structure of the CEL-III Gene and Its Expression in Transgenic Mosquitoes(A)Schematic diagram of the pMinos-EGFP-carboxypeptidaseP-CELIII-antryp1T construct used for A.stephensi germ line transformation.The construct consists of the D.melanogaster actin5c promoter (actinP),egfp selectable marker (egfp),and D.melanogaster hsp70terminator sequence (hspT),the A.gambiae carboxypeptidase promoter sequence (agcpP)plus its signal sequence (SP),fused in-frame to the coding sequence of CEL-III without its signal sequence followed by the A.gambiae trypsin terminator sequence (trypT).The left (ML)and right (MR)arms of Minos are indicated by triangles.(B)Induction of CEL-III mRNA by a blood meal.Transgenic mosquitoes were allowed to feed on a non-infected mouse and 6h later total RNA was extracted from midguts of engorged mosquitoes (Blood-fed).As a control,total RNA was extracted from midguts of sugar-fed mosquitoes (Sugar-fed).CEL-III mRNA level was examined using RT-PCR.PCR products of the endogenous carboxypeptidase gene and the S7gene were used as inducible positive controls and quantitative controls of the different mRNA preparations,respectively.These PCR products were fractionated by electrophoresis then stained with ethidium bromide.(C)Hemolytic activity of midgut contents of transgenic mosquitoes.Transgenic (CEL-III)and non-transgenic (WT)mosquitoes were offered a serum meal by membrane feeding.Six h after the meal,the supernatants of midgut lysates were added to human erythrocytes.Hemolytic activity was determined by visual examination of lysis of erythrocytes as described in Figure 1A.doi:10.1371/journal.ppat.0030192.g003CELIII-antryp1T,then transformed into the germ line of A.stephensi embryos.A total of 876embryos were injected and 22fertile G 0matings were obtained.From these,one mating produced transgenic offspring expressing the egfp selectable marker.A transgenic homozygous line was obtained and propagated.A single integration event was confirmed by Southern blot analysis using genomic DNA from G 4adults (data not shown).The transgenic line has been stably maintained by blood feeding on mice or rats for over 30generations,with no difference in reproductive fitness between transgenic and non-transgenic mosquitoes (i.e.,number of eggs and hatched larvae;data not shown).Expression profiles of the CEL-III transgene were inves-tigated by real-time (RT)-PCR (Figure 3B).CEL-III mRNA was present in the midgut cells of sugar-fed mosquitoes and was strongly induced 6h after blood ingestion,consistent with the pattern of expression of the endogenous A.stephensi carbox-ypeptidase A (AsCPA )gene,which is similar expression pattern to that of the AgCPA gene [25].To examine whether CEL-III is secreted into the midgut lumen upon blood ingestion,transgenic mosquitoes were offered a serum meal by membrane feeding.Midgut lysates of the transgenic mosquitoes before and after the serum meal contained hemolytic activity toward human erythrocytes,but not in those of non-transgenic mosquitoes,indicating CEL-III is secreted into the midgut lumen upon feeding (Figure 3C).Immunoblot analysis detected monomeric (48kDa)and oligomeric (.200kDa)forms of CEL-III in the midguts of sugar-fed transgenic mosquitoes (Figure 4).The relative mobilities of these two forms were similar to those of native CEL-III.In mosquitoes offered a blood-free ATP meal as a phagostimulant,the AgCPA promoter is activated [25,26].Under these conditions,a slightly enhanced expression of the oligomeric form was observed 24h after the pared to the native CEL-III,we estimate 5–10ng of CEL-III accumulated in a single midgut after the ATP meal.Transgenic Mosquitoes Completely Hemolyze Human Erythrocytes 24h after a Blood MealWe confirmed hemolysis of human erythrocytes 24h after a blood meal in midgut sections of a transgenic mosquito.Mosquitoes were allowed to feed on a human,then,24h after the blood feeding,gut sections were prepared for histology and stained with hematoxylin and eosin (HE).Compared to non-transgenic midguts which were filled with intact eryth-rocytes (Figure 5A and 5C),erythrocytes in the midgut of transgenic mosquito were extensively hemolyzed (Figure 5B and 5D).Lymphocytes were clearly contrasted in the midgut of transgenic mosquito (Figure 5D),but not amongst the intact erythrocytes in the midgut of non-transgenic mosquito (Figure 5C).These results are consistent with the data shown in Figure 3C,where the secretion of CEL-III into the midgut lumen caused effective hemolysis.Transgenic Mosquitoes Impair P.berghei Oocyst Formation in Both Rat and Mouse ModelsTo investigate the effect of CEL-III expression on P.berghei development,both transgenic and non-transgenic mosqui-toes were allowed to feed on the same P.berghei –infected rat and the number of oocysts formed was counted.In three experiments,the infection rate (prevalence)of transgenic mosquitoes (10.5%)was markedly reduced compared to non-transgenic mosquitoes (63.6%)(transmission blockade of prevalence,TBp;83.5%,p ,0.01).The oocyst numbers were consistently and strongly lower in transgenicmosquitoesFigure 4.CEL-III Expression in Midguts of Transgenic MosquitoesTransgenic (CEL-III)and non-transgenic (WT)mosquitoes were allowed tofeed on naı¨ve mice.After 6or 24h,midguts of engorged mosquitoes were dissected and lysed,then electrophoresed on 8%SDS-PAGE.As a control,midguts of sugar-fed mosquitoes (S)were dissected and lysed.CEL-III expression level was examined by western blotting using mouse anti-CEL-III antiserum.Each lane contains protein lysates equivalent to two midguts.The source of protein is indicated at the top of each lane (6,24h).For quantitative estimation of CEL-III per midgut,native CEL-III isolated from C.echinata body fluid was analyzed by western blotting.The amount of native CEL-III (5,25,100ng)is indicated at the top of each lane.Arrows indicate the positions of monomeric and oligomeric forms of CEL-III.doi:10.1371/journal.ppat.0030192.g004Figure 5.Hemolysis of Human Blood in Mosquito MidgutMosquitoes were allowed to feed on a human volunteer.Representative photomicrographs of engorged mosquito gut sections 24h after a blood meal are shown (HE staining,340magnification for [A and B],and 31,000magnification for [C and D]).Midgut of non-transgenic mosquitoes was filled with intact erythrocytes (A and C),with many spaces between erythrocytes.In contrast,no space is observed in the midgut of transgenic mosquitoes (B and D).Erythrocytes appear to be completely hemolyzed,and HE-stained lymphocytes cells are detectable (arrows).Scale bars in (A and B)and (C and D)are 500l m and 10l m,respectively.doi:10.1371/journal.ppat.0030192.g005(transmission blockade of intensity,TBi;range90.0to97.9%, mean90.5%,p,0.01)(Table1).For mouse experiments,TBp in Experiment1and TBi in both experiments were significantly reduced in transgenic mosquitoes.Overall,the two experiments combined,both TBp and TBi were significantly reduced in transgenic mosquitoes(p,0.01) (Table2).Vector Competence for P.berghei in Transgenic Mosquitoes Is ReducedThe impact of CEL-III expression on the ability of mosquitoes to transmit the parasite to uninfected animals (vectorial competence)was measured(Table3).Vectorial competence of transgenic mosquitoes(20%)was severely impaired,compared to non-transgenic mosquitoes(100%). After a blood meal,the salivary glands of engorged mosquitoes were dissected,and numbers of sporozoites were counted.The number of sporozoites in individual salivary glands of the transgenic mosquitoes was markedly lower than that of non-transgenic mosquitoes.Importantly,sporozoite prevalence in transgenic mosquitoes(10%)was significantly reduced compared to non-transgenic mosquitoes(60%) (Table4).These data reflect the oocyst prevalence seen in the rat experiments(Table1).Transgenic Mosquitoes Impair Oocyst Formation of P. falciparumTo investigate the effect of CEL-III expression on human Plasmodium development,both transgenic and non-transgenic mosquitoes were allowed to feed on mature P.falciparum gametocyte cultures by membrane feeding,followed by determination of the number of oocysts formed(Table5). In Experiment1,oocyst formation in transgenic mosquitoes was significantly impaired(TBi76.6%).In Experiment2,TBi was57.1%,and there was no statistically significant difference between transgenic and non-transgenic mosquitoes.Most likely,the low infection prevalence(30%)and low oocyst number(0.761.4)in Experiment2affected the statistical analysis.Overall,with the two experiments combined,trans-genic mosquitoes significantly impaired P.falciparum oocyst numbers(TBi69.1%,p,0.05),although TBp was only7.8%. DiscussionThis study demonstrates a novel‘‘proof-of-concept’’show-ing that transgenic mosquitoes expressing C-type lectin CEL-III significantly impairs development of both P.berghei and P. falciparum.We hypothezised that an environmental change in the midgut of anopheline mosquitoes by genetic manipu-Table1.Rat–P.berghei ExperimentsExperiment Mosquitoes Prevalence a TBp b Number Oocysts/Gut c(Range)TBi d 1Control72.7%(8/11)— 4.366.5(0–22)—CEL-III9.4%(3/32)87.1%e0.461.6(0–8)90.7%e 2Control58.3%(14/24)— 4.067.5(0–28)—CEL-III14.3%(2/14)75.5%f0.461.2(0–8)90.0%e 3Control66.7%(6/9)— 4.766.6(0–20)—CEL-III9.1%(1/11)86.4%f0.160.3(0–1)97.9%e Average Control63.6%(28/44)— 4.266.9(0–28)—CEL-III10.5%(6/57)83.5%e0.461.3(0–8)90.5%eTransgenic(CEL-III)and non-transgenic(control)mosquitoes were fed on the same P.berghei–infected rats.On day15,the guts were dissected and the number of oocysts per gut was determined.a Percentage of infected mosquitoes(actual numbers in parentheses).b Transmission blockade of prevalence(TBp)¼100À[(prevalence of transgenic mosquitoes)/(prevalence of control mosquitoes)3100].c The number of oocysts per midgut(intensity)are shown as means6SEM.d Tansmission blockade of intensity(TBi)¼100À[(average oocyst number per gut in transgenic mosquitoes/average oocyst number per gut in control mosquitoes)3100].e Statistical significance(p,0.01),as calculated by the Mann-Whitney U test.f Statistical significance(p,0.05),as calculated by the Mann-Whitney U test.doi:10.1371/journal.ppat.0030192.t001Table2.Mouse–P.berghei ExperimentsExperiment Mosquitoes Prevalence a TBp b Number Oocysts/Gut c(Range)TBi d 1Control83.3%(15/18)—50.2678.9(0–300)—CEL-III44.0%(11/25)47.2%f10.6622.3(0–100)78.9%e 2Control75.0%(12/16)—58.3668.3(0–217)—CEL-III33.3%(4/12)55.6% 3.367.1(0–24)94.3%e Average Control79.4%(27/34)—54.0673.1(0–300)—CEL-III40.5%(15/37)49.0%e8.2618.9(0–100)84.8%eTransgenic(CEL-III)and non-transgenic(control)mosquitoes were fed on the same P.berghei–infected mice.On day15,the guts were dissected and the number of oocysts per gut was determined.a,b,c,d Prevalence,TBp,intensity,and TBi are described as Table1.e Statistical significance(p,0.01),as calculated by the Mann-Whitney U test.f Statistical significance(p,0.05),as calculated by the Mann-Whitney U test.doi:10.1371/journal.ppat.0030192.t002lation could provide a new strategy for interrupting parasitedevelopment.CEL-III is a C-type,galactose/N-acetylgalactos-amine(GalNAc)-specific lectin isolated from the bodyfluid of the marine invertebrate C.echinata.This lectin exhibits strong and rapid hemolytic activity and cytotoxicity through pore formation in target cell membranes.CEL-III is thought to play an important role in innate defense systems of C.echinata and therefore has the potential not only to change the environment of the mosquito midgut by rapid hemolysis of a blood meal,but also to act directly as a toxin against parasites.For CEL-III,the N-terminal region contains two carbohy-drate binding domains that have homology with the B-chains of ricin and abrin[20,27,28]and binds to the carbohydrate chains on the surface of the target cell membrane by its lectin activity.The C-terminal hydrophobic region that has anti-bacterial activity is believed to permeabilize the lipid bilayer of target microbes and cells[23].CEL-III may therefore exhibit direct effector function to kill parasites.Alternatively, similar to other antimicrobial peptides or lectins,CEL-III may induce cells to undergo apoptosis[29].In the transgenic mosquitoes,CEL-III is constitutively expressed prior to blood meal ingestion and accumulates in the midgut.Expression level of CEL-III was enhanced and reached a peak at5–10ng per midgut after a protein-free ATP meal.This amount is sufficient to completely hemolyze human erythrocytes in3l l-whole blood.As A.stephensi usually imbibes in less than2.2l l in a single blood meal[30],this result is consistent with the observation that complete hemolysis occurred in the midgut at24h after a blood meal. Within minutes of ingestion,both male and female gametocytes escape from enveloping erythrocytes,then transform into male and female gametes.The male gametes produce eightflagellate microgametes in a process termed exflagellation,fertilizing the female gametes,giving risefirst to zygotes then motile ookinetes.In the rat model,CEL-III accumulation in the midgut before a blood meal is likely to hemolyze erythrocytes infected with gametocytes immedi-ately after a blood meal.As a result,extracellular gametocytes may be killed before differentiation.Although CEL-III cannot cause hemolysis of mouse erythrocytes,oocyst formation was also significantly reduced in the mouse model suggesting that direct parasite toxicity may be the dominant impact of the peptide.Preliminary observations suggest CEL-III reduces the efficiency of fertilization(S.Y.unpublished data).Addition-ally CEL-III bound to cultured ookinetes correlating with a strong killing effect on the parasites(IC50¼15nM)at100-to 1,000-fold lower concentrations in vitro,when compared to other reported effector molecules,such as cecropin-like peptide[9],defensin[31],Vida3[10],SM1[7],and PLA2[8]. In the rat model,the higher TBi(90.5%)may be due to additional hemolysis compared to that of the mouse model (84.8%).Although the binding specificity and mechanism by which CEL-III kills parasites in mosquitoes is unknown,findings from this study suggest that CEL-III may cause lethal damage to the female gamete and ookinete by pore formation following oligomer formation.For P.berghei,the key property,as proposed in1968by Curtis[32],of vectorial competence was demonstrably and severely impaired,as measured by the relative inefficiency of transgenic mosquitoes to infect naı¨ve mice compared to wild-type.Importantly,CEL-III transgenic mosquitoes impair sporogonic development of P.falciparum.To our knowledge, this is thefirst demonstration of stably engineered anophe-lines that affect the human Plasmodium transmission dynamics of a human pared to the P.berghei-rat model,the TBi of P.falciparum is numerically lower(69.1%).One possible explanation for the lower TBi is that membrane feeding of in vitro cultured P.falciparum gametocytes does not contain leukocytes that may remain active in the mosquito blood meal and kill or phagocytose the liberated extracellular parasites[33,34].In malaria endemic areas,multiple infections with Plasmo-dium species and strains are often observed.Those effector gene products must inhibit development of all species and strains of Plasmodium in the mosquito.As CEL-III targets erythrocytes,the‘‘vehicles’’for this parasite,as well as ookinetes,this transgenic mosquito may prove to be refractory to all species and strains of Plasmodium,including P.falciparum and P.vivax.Transgenic mosquitoes must have a minimalfitness cost,as such costs would reduce the effectiveness of the genetic drive mechanisms used to introduce transgenes intofield mosquito populations.To date,there have been no single or cumulative toxic effectsTable3.Vectorial Competence of Transgenic Mosquitoes%Infected Mice b(Number of Infected/Total)Control CEL-III Vector competence a(3mosquito bites/mouse6)100%(10/10)20%(1/5)Transgenic(CEL-III)and non-transgenic(control)mosquitoes were fed on the same P. berghei–infected rat.To measure transmission,three to six mosquitoes were fed on individual naı¨ve mice21days after the infectious blood meal.a Six mosquitoes were allowed to feed on individual naı¨ve mice21days after ingesting the infectious blood meal.Of six mosquitoes,at least three mosquitoes were observed to feed on each mouse.b The infection status of each mouse was established by examining a smear of tail vein blood on alternate days.Mice that had no parasites by day30were considered to be non-infected.doi:10.1371/journal.ppat.0030192.t003Table4.Sporozoite Infectivity of Salivary Glands of Transgenic MosquitoesNumber of Sporozoites(spz)/Salivary Glands aNumber of MosquitoesControl CEL-III024181spz500121500,spz5,0001915,000,spz50%Infected mosquitoes(Number infected/total)60%(36/60)10%(2/20)bImmediately after blood feeding(Table3),engorged mosquitoes(20transgenic and60 non-transgenic mosquitoes)were picked up and the salivary glands were dissected and the number of sporozoites per salivary gland was determined.a Individual salivary glands were observed for sporozoites by phase contrast microscopy after crushing the glands under a cover slip and the number of sporozoites were counted and scored.b The number of sporozoites was significantly lower(p,0.001)in transgenic than in non-transgenic mosquitoes,as calculated by the Mann-Whitney U test.doi:10.1371/journal.ppat.0030192.t004。

相关文档
最新文档